WO2004047749A2 - Modulation purinergique d'odeur - Google Patents

Modulation purinergique d'odeur Download PDF

Info

Publication number
WO2004047749A2
WO2004047749A2 PCT/US2003/037389 US0337389W WO2004047749A2 WO 2004047749 A2 WO2004047749 A2 WO 2004047749A2 US 0337389 W US0337389 W US 0337389W WO 2004047749 A2 WO2004047749 A2 WO 2004047749A2
Authority
WO
WIPO (PCT)
Prior art keywords
agonist
purinergic receptor
atp
antagonist
receptor
Prior art date
Application number
PCT/US2003/037389
Other languages
English (en)
Other versions
WO2004047749A3 (fr
Inventor
Mary Lucero
Colleen Hegg
Original Assignee
University Of Utah Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Utah Research Foundation filed Critical University Of Utah Research Foundation
Priority to US10/535,774 priority Critical patent/US7557092B2/en
Priority to AT03789946T priority patent/ATE542423T1/de
Priority to EP03789946A priority patent/EP1624753B1/fr
Priority to AU2003294462A priority patent/AU2003294462C1/en
Priority to CA002507044A priority patent/CA2507044A1/fr
Publication of WO2004047749A2 publication Critical patent/WO2004047749A2/fr
Publication of WO2004047749A3 publication Critical patent/WO2004047749A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites

Definitions

  • BACKGROUND A longstanding dogma, based on lack of efferent synapses, is that odor sensitivity is not modulated at the level of the olfactory receptor neurons (O Ns). The sensation of smell occurs in part by the activation of smell receptors present on the ORNs. This activation begins through contact of the chemical signature responsible for the odor with a smell receptor on the ORN. There is a need to be able to modulate sensitivity to smell, to for example, decrease sensitivity to smell in noxious environments and increase sensitivity to smell for environments in which it is desirable to smell the odors. Disclosed are methods and compositions which modulate the sensitivity to odor responsiveness.
  • compositions and methods relate to the modulation of smell. It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive.
  • Figure 1 shows the identification of purinergic receptors in the olfactory epithelium (OE).
  • FIG. 1(A) shows RT-PCR analysis of P2X 2 and P2Y 2 mRNA in rat OE and bulb.
  • the 643-bp product represents the P2Y isoform; the 499-bp product represents the P2X 2.j isoform, and the 292-bp product is the P2X 2 2 isoform.
  • Control ⁇ -actin (867 bp) and neuron specific enolase (NSE; 753 bp) RT-PCR reactions are shown. +, Indicates reverse transcribed mRNA; -, indicates omission of reverse transcriptase.
  • Figures 1(B, C) show neonatal mouse OE showing punctate P2X and P2X 4 _IR (green) in olfactory marker protein (OMP)-positive (red) axons and olfactory receptor neurons (ORNs; closed arrowheads) and in OMP-negative ORNs and basal cells (open arrowheads).
  • SC sustentacular cell layer
  • BC basal cell layer
  • NL nerve layer
  • C cribriform plate
  • NB nerve bundle.
  • Figure 1(D) shows neonatal mouse P2Y2 receptor-IR (green) occurs in ORNs (closed arrowheads), in the sustentacular cell layer (open arrowheads), and in a Bowman's gland (BG, *).
  • Figure 1(E) shows P2X1 receptor antibody preabsorption.
  • LP lamina limbal
  • Figure 2 shows ATP evokes inward currents and increases intracellular Ca in cultured mouse olfactory receptor neurons (ORNs).
  • A Current responses to 10 ⁇ M ATP in two nystatin-patched ORNs held at -110 mV. Lower trace shows the ATP stimulus profile recorded separately with an open electrode. Inset, enlarged, compressed view of current from cell 1.
  • B Confocal images from fluo-4 AM loaded ORNs taken before (left), and during (right) superfusion of 5 ⁇ M ATP. Scale bar, 50 ⁇ m.
  • Figures 3(A1-D4) show confocal images from a fluo-4 AM-loaded mouse olfactory epithelium (OE) slice during application of (A) odors (10 ⁇ M n-amyl acetate + 10 ⁇ M R-carvone),
  • FIG. 1 shows time course of odor- and P2R-agonist-evoked Ca 2+ transients.
  • Time points indicated by black triangles correspond to frame numbers in A1-D4.
  • Representative odor-responsive olfactory receptor neurons are indicated by solid white triangles (al-a4; 6/11 ORNs marked) and as solid lines in a5.
  • One odor-responsive ORN solid triangle in bl-d4) and one sustentacular cell (SC, open triangle in B1-D4) are shown in the time course (B5-
  • Figure 4(B); identified by location and lack of odor response; n 122), that had increases in [Ca 2+ ]j evoked by non-selective purinergic receptor agonists (ATP, ATP ⁇ S), P2Y-selective agonists (UTP, ADP, MeSADP) and P2X-selective agonists ( ⁇ -MeATP).
  • ATP purinergic receptor agonist
  • ATP ⁇ S P2Y-selective agonists
  • UDP ADP
  • MeSADP MeSADP
  • ⁇ -MeATP P2X-selective agonists
  • Figure 5 shows that ATP modulates odor responses.
  • Figure 5(A) Suppression or Figure 5(B) enhancement of [Ca ]i due to co-application (Co-App.) compared to the summed response of ATP and odor. Shown are responses to odor (10 ⁇ M n-amyl acetate + 10 ⁇ M R-carvone), 10 ⁇ M ATP, control Ringers solution, or co-application of odor + ATP from individual mouse ORNs in olfactory epithelium slices.
  • Figure 5(C) Bar graph showing suppression and enhancement from the 2 individual ORNs shown in A and B. The sum of the responses to individual application of ATP and odor were normalized to 1.0 (stacked bars) and the response to co-application of ATP and odor were normalized to the summed response (black bars).
  • Figure 6 shows the activation of specific purinergic receptor subtypes modulates odor responses.
  • Figures 6 (A, C, E) Representative calcium transients in response to odor (10 ⁇ M n-amyl acetate + 10 ⁇ M R- carvone), 10 ⁇ M purinergic receptor (P2) agonists, or co-application of odor + P2 agonists from individual mouse ORNs in Fluo-4 AM loaded olfactory epithelium slices.
  • Black triangles correspond to the time of loop injection of the odors or P2 agonists.
  • Black circles correspond to the predicted peak amplitude of co- application (obtained by adding the estimated odor and P2 agonist values; refer to data analysis section for details).
  • Figure 7 shows examples of the growing family of ATP-gated ion channels.
  • the predicted primary amino acid sequences of cloned P2X ⁇ -P2X(j receptor subtypes show that these proteins share approximately 40% sequence identity (gray shading) overall.
  • Ten invariant cysteine residues (*) located within the presumptive extracellular loop may be essential for stabilizing a ligand-binding pocket through the formation of specific disulfide bonds.
  • Putative transmembrane -helices are delimited with black bars labeled Ml and M2.
  • a potential pore loop region akin to that found in potassium channels corresponds to the portion of M2 denoted as (H5).
  • Figure 8 shows a diagram depicting a proposed transmembrane topology for P2X2 protein showing both N- and C-terminals in the cytoplasm.
  • Two putative membrane spanning segments (Ml and M2) traverse the lipid bilayer of the plasma membrane and are connected by a hydrophilic segment of 270 amino acids. This putative extracellular domain is shown containing two disulfide-bonded loops (S-S) and three N-linked glycosyl chains (triangles).
  • S-S disulfide-bonded loops
  • triangles The P2X2 cDNA was sequenced on both strands using Sequanase. (From Brake et al., 1994).
  • Figure 9 shows a predicted secondary structure of the human P2Y1 -receptor.
  • Bold circles and letters highlight amino acids that most likely contribute to the nucleotide binding site within the transmembrane regions.
  • a change of these residues by site-directed mutagenesis caused both an increase in half-maximal concentrations of agonists such as 2-methylthio-ADP activating phospholipase C (Jiang et al. 1997) and a reduction of the antagonistic potency of the nucleotide antagonist MRS 2179 (Moro et al. 1998).
  • the dashed lines show predicted disulphide bridges (Hoffmann et al. 1999).
  • Glu at the position 209 and Arg at the position 287 may form additional (probably low affinity) binding sites ("meta-binding sites”; see Moro et al. 1999). Potential sites for N-linked glycosylation are not indicated (TM transmembrane region, EL extracellular loop).
  • Figure 10 shows the alignment of the amino acid composition of the predicted transmembrane regions (TMs) 3, 5, 6 and 7 of the human P2Y , P2Y 2 -, P2Y 4 -, P2Y 6 - and P2Y ⁇ -receptors (for each subtype, the principal physiological agonist is shown in parentheses; please note that the human P2Y 2 -receptor is activated by both UTP and ATP).
  • Bold letters show a pattern of similarity in amino acid composition, which may be responsible for the pharmacological properties of the subtype. The respective residues are conserved within species.
  • Figure 12 shows the results of the addition of antagonists and odor stimulants on nerve cells.
  • Figure 13 shows ATP suppresses cyclic nucleotide-induced electrical responses in olfactory epithelium.
  • A shows representative EOG responses from OE slices attributable to Ringer's solution, odor, and a cyclic nucleotide mixture (100 ⁇ M IBMX, 50 ⁇ M CPT-cAMP, and 50 ⁇ M 8-Br-cGMP). Filled triangles correspond to the time of loop injection of the test solutions.
  • (B) shows representative on-cell current-clamp recording from an ORN in an OE slice. Various test solutions were superfused onto the slice for 30 seconds, indicated by the shaded region. The cell was allowed to recover for 7 minutes after each test application.
  • compositions and methods are not limited to specific synthetic methods, specific recombinant biotechnology methods unless otherwise specified, or to particular reagents unless otherwise specified, as such can, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. A. Definitions
  • Primer are a subset of probes which are capable of supporting some type of enzymatic manipulation and which can hybridize with a target nucleic acid such that the enzymatic manipulation can occur.
  • a primer can be made from any combination of nucleotides or nucleotide derivatives or analogs available in the art, which do not interfere with the enzymatic manipulation.
  • Probes are molecules capable of interacting with a target nucleic acid, typically in a sequence specific manner, for example through hybridization. The hybridization of nucleic acids is well understood in the art and discussed herein. Typically a probe can be made from any combination of nucleotides or nucleotide derivatives or analogs available in the art.
  • Coapplication is defined as the application of one or more substances simultaneously, such as in the same formulation or consecutively, within a time frame such that each substance is active during a point when the other substance or substances are active.
  • test compound is defined as any compound to be tested for its ability to interact with a purinergic receptor, e.g., an epithelial Ca 2+ entry channel agonist or antagonist.
  • test components include, for example, drugs, molecules, and compounds that come from combinatorial libraries where thousands of such ligands are screened by drug class.
  • control levels or "control cells” are defined as the standard by which a change is measured, for example, the controls are not subjected to the experiment, but are instead subjected to a defined set of parameters, or the controls are based on pre- or post-treatment levels.
  • compositions disclosed herein have certain functions, such as enhancing or reducing odor sensitivity.
  • Disclosed herein are certain structural requirements for performing the disclosed functions, and it is understood that there are a variety of structures which can perform the same function which are related to the disclosed structures, and that these structures will ultimately achieve the same result, for example stimulation or inhibition of smell.
  • Purinergic nucleotides are important neuromodulators of auditory and visual systems. Disclosed herein is the existence and activity of purinergic receptors in mammalian olfactory epithelium, such as mouse or human, determined through immunohistochemistry, elecfrophysiology and calcium imaging. P2X and P2Y receptors, such as P2Y2, P2X1 and P2X4 immunoreactivity (-IR) was present on the dendrites, soma and axons of olfactory marker protein + (OMP) ORNs, and in the olfactory nerve, glomular and mitral cell layers of the olfactory bulb.
  • OMP olfactory marker protein +
  • OE olfactory epithelial
  • P2X and P2Y receptor subtypes are expressed in the olfactory epithelium and that P2X and P2Y agonists and antagonists modulation of odor responses, such as the agonist ATP, can be dependent on the subtype(s) of purinergic receptors expressed.
  • ATP and ATP analogs modulate odor responses in olfactory receptor neurons.
  • ATP released in the olfactory epithelium following noxious stimuli provides a physiological source for a neuromodulatory substance independent of efferent innervation.
  • Peripheral ATP-mediated odor suppression is a mechanism for reduced olfactory sensitivity during exposure to olfactotoxins.
  • P2X receptors form Ca 2+ -permeable nonselective cation channels that allow Ca 2+ influx from the extracellular fluid.
  • Most of the 8 functional P2Y receptors identified to date act via G-protein coupling to activate phospholipase C, leading to production of inositol triphosphates and mobilization of Ca 2+ from internal stores (Dubyak and el-Moatassim, 1993); however, a few P2Y receptors couple to adenylate cyclase (Ralevic and Burnstock, 1998). All of the components of both transduction pathways have been identified in ORNs (Schild and Restrepo, 1998). Although purines are odorants for aquatic vertebrates (Kang and Caprio, 1995) and invertebrates
  • extracellular purinergic nucleotides and their receptors in mammalian, such as human, olfactory epithelium exist.
  • RT-PCR and immunoliistochemistry and physiological studies show that sustentacular support cells express P2Y receptors and that ORNs express both P2X and P2Y receptors.
  • Regionally localized purinergic receptors are consistent with extracellular ATP having multiple roles in the peripheral olfactory system.
  • ATP differentially modulates the odor responsiveness of ORNs.
  • P2X and/or P2Y receptor subtypes expressed in the ORN can determine whether the odor- response is enhanced or inhibited in the presence of ATP.
  • adenosine or PI receptors There are two main families of purine receptors, adenosine or PI receptors, and P2 receptors, recognizing primarily ATP, ADP, UTP, and UDP (Table 1).
  • Adenosine/Pl receptors couple to G proteins and have been further subdivided, based on molecular, biochemical, and pharmacological evidence into four subtypes, A], A 2A , A 2B , and A 3 .
  • P2 receptors divide into two families of ligand-gated ion channels and G protein-coupled receptors termed P2X and P2Y receptors, respectively.
  • Table 1 sets forth seven mammalian P2X receptors (P2Xj- 7 ) and five mammalian P2Y receptors (P2Y ⁇ , P2Y 2 , P2Y 4 , P2Y 6 , P2Y n ) which have been cloned and characterized.
  • P2X receptors are ATP-gated ion channels which mediate rapid (within 10 ms) and selective permeability to cations (Na + , K + and Ca 2+ ) (Bean, 1992; Dubyak and el-Moatassim, 1993; North, 1996). They are typically found on excitable cells (smooth muscle cells, neurons, and glial cells) and mediate fast excitatory neurotransmission to ATP in both the central and peripheral nervous systems. This contrasts with the slower response (less than 100 ms) to ATP acting at metabofropic P2Y receptors, which involves coupling to G proteins and second-messenger systems.
  • P2Xj to P2X 7 Seven functional P2X receptor proteins (P2Xj to P2X 7 ) have been cloned and fo ⁇ n homomeric ion channels with distinct pharmacological profiles when expressed in Xenopus oocytes (Table 2).
  • the P2X 7 receptor is considered separately below, because it is functionally unique among P2X receptors in being able to act as a non-selective pore.
  • Functional cDNAs encoding the first two members of this family, P2Xj and P2X 2 were isolated from vas deferens smooth muscle and PC 12 pheochromocytoma cells, respectively, using an expression cloning strategy in Xenopus oocytes (Brake etal 1994, Valera et al 1994). In each case, expression of a single cDNA clone in oocytes or transfected mammalian cells is sufficient to direct the synthesis of functional, presumably homomeric ATP-gated ion channel complexes on the surface of these cells.
  • P2X] and P2X 2 receptors are clearly related at the level of primary amino acid sequence and predicted secondary structure.
  • P2X proteins that have been cloned are receptor subunits, not actual receptors since a single 2 transmembrane subunit alone cannot form an ion channel.
  • the proteins have 379 to 472 amino acids and are believed to insert into the cell membrane to form a pore comprising two hydrophobic transmembrane domains (Ml and M2), with much of the protein occurring extracellularly as an intervening hydrophilic loop (figure 8).
  • P2X subunits contain a region, that resembles the H5 pore loop domain of potassium channels, and it is possible that this segment (just amino-tenninal to M2), also contributes to the pore of ATP-gated channels.
  • H5 domain consensus sequence and its location relative to M2, among the six cloned P2X receptor subtypes.
  • the overall structure of the receptor most closely resembles that of amiloride-sensitive epithelial Na + channels.
  • the putative extracellular loop of cloned receptors P2X ⁇ to P2X 7 has 10 conserved cysteine residues, 14 conserved glycine residues and 2 to 6 potential N-linked glycosylation sites.
  • disulfide bridges may form the structural constraints needed to couple the ATP-binding site to the ion pore. Most of the conserved regions are in the extracellular loop, with the transmembrane domains being less well-conserved.
  • P2X receptors are believed to form a heterologous complex in biological tissues. Although their subunit stoichiometry is unknown, SDS polyacrylamide gel electrophoresis estimates of the relative molecular mass of the recombinant P2X ⁇ and P2X 3 receptors determined under non-denaturing conditions (Nicke etal, 1998) suggest a combination of three subunits (or multiples of three subunits).
  • Both cloned P2X 7 and endogenous P2X 7 -like receptors are unique in that, under physiological conditions they are selectively permeable to small cations only, but in the presence of low divalent cation levels and ATP, the P2X 7 channel can convert to a pore, permeable to small molecules as well as ions.
  • the P2X 7 receptor and its endogenous counte ⁇ art is structurally similar to other P2X receptors, except for the fact that it has a significantly longer intracellular C-tenninal (240 amino acids) than other P2X receptors, of which at least the last 177 amino acids are crucial for the induction of the non-selective pore (Su ⁇ renant et al, 1996).
  • P2X 7 receptor is not typically present in mammalian olfactory epithelium.
  • P2Y receptors are purine and pyrimidine nucleotide receptors that are coupled to G proteins. Most P2Y receptors act via G protein coupling to activate PLC leading to the formation of IP 3 and mobilization of intracellular Ca 2+ . Coupling to adenylate cyclase by some P2Y receptors has also been described. The response time of P2Y receptors is longer than that of the rapid responses mediated by P2X receptors because it involves second-messenger systems and/or ionic conductances mediated by G protein coupling. Five mammalian P2Y receptors (P2Y P2Y 2 , P2Y 4 , P2Y 6 , P2Yn) have been cloned, and functionally characterized and show distinct pharmacological profiles (Table 3).
  • P2Y receptors are 308 to 377 amino acid proteins with a mass of 41 to 53 kDa after glycosylation.
  • the tertiary structure of P2Y receptors is similar to that of other seven transmembrane domain G protein- coupled receptors ( Figure 9).
  • a model of the P2Y receptor based on the primary sequence of the P2Yi receptor and using the structural homolog rhodopsin as a G protein-coupled receptor template, has identified positively charged amino acid residues in transmembrane regions 3, 6, and 7 that may be involved in ligand binding by electrostatic interactions with the phosphates of ATP (Van Rhee et al, 1995) ( Figure 10). Several of these amino acids are conserved in other G protein-coupled receptors.
  • Extracellular ATP plays an important role in cellular signaling and acts as a cotransmitter or neuromodulator in sensory systems (Thorne and Housley, 1996).
  • ATP can be released from synaptic vesicles in trigeminal afferents that innervate the olfactory epithelium and detect noxious chemicals (Finger et al., 1990;Getchell and Getchell, 1992), or via plasma membrane nucleotide transport proteins (Roman et al., 1997).
  • ischemic, stressed, and injured cells release ATP in large amounts.
  • P2 receptors have broad natural ligand specificity, recognizing ATP, ADP, UTP, UDP, and the diadenosine polyphosphates (Table 1).
  • the chemical structures of some principal P2 receptor agonists and antagonists are illustrated in Figure 11.
  • P2X selective agonists are the stable ATP analogs ⁇ , ⁇ - meATP and ⁇ , ⁇ -meATP, which if effective, strongly imply actions at P2X receptors (typically at P2Xi and P2X 3 subtypes) and are generally inactive at P2Y receptors.
  • ADP adenosine 5'-0-(2- thiodiphosphate)(ADP ⁇ S,) and UTP
  • Receptor type Ion channel Nonselective pore G protein-coupled: G q ⁇ , G b
  • P2X/P2Y-selective oc ⁇ -meATP 1 , ⁇ , ⁇ -meATP', BzATP 3 ADP C , UTP m , UTP ⁇ S j , UDP n , 2C1-ADP 0
  • P2Y ⁇ and endogenous P2Y ⁇ -like receptors and P2Y ADP receptors couple to G q/n proteins.
  • Some endogenous P2Y like receptors activate K + channels via interactions with their G protein subunits.
  • ATP is an antagonist at P2YADP receptors.
  • AC adenylate cyclase
  • ADP ⁇ F adenosine 5'-0-(2-fluoro)-diphosphate
  • ADP ⁇ S adenosine 5'- 0-(2-thio-diphosphate
  • cAMP adenosine 3',5'-cyclic monophosphate
  • A3P5PS adenosine 3'-phosphate 5'- phosphosulfate
  • ATP ⁇ S adenosine 5'-0-(3- thiotriphosphate
  • BzATP 3'-0-(4-benzoyl)benzoyl ATP
  • DAG diacylglycerol
  • DIDS 4,4'-diisothio- cyanatostilbene-2,2'-disulfonate
  • FPL 66096 2-propylthiothio-
  • the calcium transient evoked by co-application is less than the sum of the calcium transients evoked by the individual components then there is an inhibiting effect on the olfactory response.
  • 62% (21/26 cells) exhibited a significant decrease in the summed [Ca 2+ ]; increase.
  • ATP reduced the expected combined effect of the ATP and the odor, and thus will act as an odor suppressant.
  • activation of P2Y receptors reduced sensitivity to odors.
  • the P2Y selective agonists UTP and ADP- ⁇ S suppressed the co-application evoked calcium transient indicating they can act as odor suppressants.
  • similar experiments were performed with P2X and P2Y selective agonists giving similar results.
  • compositions and methods for inhibiting the odor response of an ORN are disclosed. Inhibition of the response can be determined by performing the transient calcium flux assays as discussed herein. Typically these assays can be performed in the presence or absence of the odor. Thus, compositions which inhibit the ORN response can be compositions which in a calcium transient flux assay, the presence of the composition and the odor together, produces a transient calcium flux that is less than the sum of the odor induced flux alone and the composition induced flux alone.
  • compositions that have a ratio of less than or equal to 0.01, 0.03, 0.05, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.52, 0.55, 0.6, 0.64, 0.65, 0.69, 0.7, 0.72, 0.75, 0.80, 0.83, 0.85, 0.87 0.90, 0.92, 0.95, 0.97, or 0.99.
  • the ratio can be expressed in te ⁇ ns of a range of these individual ratios, such as 0.72 to 0.92, for example, or 0.52 to 0.64, or 0.69 to 0.83.
  • P2X selective agonists and P2Y selective agonists Disclosed are P2X directed agonists and P2Y directed agonists.
  • P2X directed agonists and P2Y directed agonists are any agonist that has a greater effect on a P2X receptor than on a P2Y receptor.
  • a P2Y directed agonist is any agonist that has a greater effect on a P2Y receptor than on a P2X receptor.
  • P2X agonists and P2Y agonists can be determined by comparing the activity to known selective agonists, such as those discussed herein. It is understood that the level of activity of each selective agonist discussed herein, is disclosed.
  • P2 agonists that interact with any P2 receptor. It is understood that many P2X and P2Y agonists can be both a selective agonist as well as a directed agonist. For example, UTP can be a selective and a directed P2Y agonist.
  • P2X and P2Y agonists inhibit ORN response to odor stimulants, so too, antagonists of P2X and P2Y receptors can lead to an enhancement of the smell response.
  • P2X antagonists such as those disclosed in Table 4, for example, act at P2X receptors and P2Y antagonists, such as those disclosed in Table 4, for example, act at P2Y receptors, and thus can be stimulators of odor responsiveness. It is understood that the assays, measurements, and functional limitations, as discussed, herein for agonists are applicable for antagonists as well.
  • B an antagonist
  • antagonists have an opposite effect on a receptor than an agonist, and application of the disclosed methods and limitations can be thus applied to antagonists, as they were for agonists.
  • P2X selective antagonists and P2Y selective antagonists Disclosed are P2X selective antagonists and P2Y selective antagonists. Disclosed are P2X directed antagonists and P2Y directed antagonists. In certain embodiments, a P2X directed antagonist is any antagonist that has a greater effect on a P2X receptor than on a P2Y receptor. Likewise, in certain embodiments, a P2Y directed antagonist is any antagonist that has a greater effect on a P2Y receptor than on a P2X receptor. In other embodiments, P2X antagonist and P2Y antagonist can be determined by comparing the activity to known selective antagonists, such as those discussed herein. It is understood that the level of activity of each selective antagonist discussed herein, is disclosed. Also disclosed are P2 antagonists that interact with any P2 receptor. It is understood that many P2X and P2Y antagonists can be both a selective antagonist as well as a directed antagonists.
  • compositions comprising administering a composition to the subject, wherein the composition is an antagonist of a P2X or P2Y purinergic receptor.
  • the antagonist can increase the odor sensitivity of the subject, which can be desirable to those with olfactory impairments. Increasing odor sensitivity is also desirable in conjunction with a pleasant smell.
  • the antagonist can reduce basal Ca 2+ levels in olfactory receptor neurons which will make the neurons more excitable during subsequent odor stimulation thereby increasing the odor sensitivity of the subject.
  • the antagonist can increase the ratio of observed coapplication-evoked calcium transient compared to the individual odor peak amplitudes in a cell activation assay, as discussed above.
  • analogs of ATP can be made at the base moiety, the sugar moiety, and the phosphate moiety, as discussed herein.
  • the base moiety can be considered as adenin-9-yl (A).
  • A adenin-9-yl
  • the sugar moiety of a nucleotide is typically a ribose or a deoxyribose.
  • the phosphate moiety of a nucleotide is typically pentavalent phosphate.
  • a non-limiting example of a nucleotide would be 3'-AMP (3'-adenosine monophosphate), ADP, and ATP.
  • ATP analogs can have modifications to the base moiety which would include natural and synthetic modifications of A, such as hypoxanthin-9-yl (I), and 2-aminoadenin-9-yl, 2-aminoadenine, xanthine, 6-methyl and other alkyl derivatives of adenine, 2-propyl and other alkyl derivatives of adenine, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines, 7-methyladenine, 8-azaadenine, 7-deazaadenine and 3-deazaadenine, and 0-6 substituted adenines, including 2-aminopropyladenine.
  • A such as hypoxanthin-9-yl (I), and 2-aminoadenin-9-yl, 2-aminoadenine, xanthine, 6-methyl and other alkyl derivatives of adenine, 2-propyl and other alkyl
  • ATP analogs can also include modifications of the sugar moiety. Modifications to the sugar moiety would include natural modifications of the ribose and deoxy ribose as well as synthetic modifications. Sugar modifications include but are not limited to the following modifications at the 2' position: OH; F; 0-, S-, or N-alkyl; 0-, S-, or N-alkenyl; 0-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted Ci to C ⁇ 0 , alkyl or C 2 to Cio alkenyl and alkynyl.
  • 2' sugar modifications also include but are not limited to -0[(CH 2 ) n 0] m CH 3 , -0(CH 2 ) n OCH 3 , -0(CH 2 ) n NH 2 , -0(CH 2 ) n CH 3 , - 0(CH 2 ) n -ONH 2 , and -0(CH 2 ) n ON[(CH 2 ) n CH 3 )] 2 , where n and m are from 1 to about 10.
  • ATP analogs can have other modifications at the 2' position and include but are not limited to: Cj to C 10 lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH 3 , OCN, CI, Br, CN, CF 3 , OCF 3 , SOCH 3 , S0 2 CH 3 , ON0 2 , N0 2 , N 3 , NH 2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, and polyalkylamino.
  • Modified sugars would also include those that contain modifications at the bridging ring oxygen, such as CH 2 and S.
  • Nucleotide sugar analogs can also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.
  • sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.
  • There are numerous United States patents that teach the preparation of such modified sugar structures such as 4,981,957; 5,118,800; 5,319,080; 5,359,044; 5,393,878; 5,446,137; 5,466,786; 5,514,785; 5,519,134; 5,567,811; 5,576,427; 5,591,722; 5,597,909; 5,610,300; 5,627,053; 5,639,873; 5,646,265; 5,658,873; 5,670,633; and 5,700,920, each of which is herein inco ⁇ orated by reference in its entirety.
  • ATP analogs can also be modified at the phosphate moiety.
  • Modified phosphate moieties include but are not limited to those that can be modified so that the linkage between two nucleotides contains a phosphorothioate, chiral phosphorothioate, phosphorodithioate, phosphofriester, aminoalkylphosphotriester, methyl and other alkyl phosphonates including 3'-alkylene phosphonate and chiral phosphonates, phosphinates, phosphoramidates including 3 '-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates.
  • nucleotide analogs need only contain a single modification, but can also contain multiple modifications within one of the moieties or between different moieties.
  • Nucleotide substitutes are molecules having similar functional properties to nucleotides, but which do not contain a phosphate moiety, such as peptide nucleic acid (PNA). Nucleotide substitutes are molecules that will recognize nucleic acids in a Watson-Crick or Hoogsteen manner, but which are linked together through a moiety other than a phosphate moiety. Nucleotide substitutes are able to conform to a double helix type structure when interacting with the appropriate target nucleic acid.
  • PNA peptide nucleic acid
  • Nucleotide substitutes are nucleotides or nucleotide analogs that have had the phosphate moiety and/or sugar moieties replaced. Nucleotide substitutes do not contain a standard phosphorus atom. Substitutes for the phosphate can be for example, short chain alkyl or cycloalkyl intemucleoside linkages, mixed heteroatom and alkyl or cycloalkyl intemucleoside linkages, or one or more short chain heteroatomic or heterocyclic intemucleoside linkages.
  • Numerous United States patents disclose how to make and use these types of phosphate replacements and include but are not limited to 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is herein inco ⁇ orated by reference.
  • non-selective, P2X selective and P2Y selective ATP analogs there are ATP selective agonists and ATP selective antagonists.
  • non-selective purinergic receptor agonists are ATP, ATP ⁇ S, and AMP (Table 4).
  • P2Y-'selective' agonists are UTP, ADP, and MeS-ADP (Table 4).
  • an example of a P2X-'selective' agonist is ⁇ -methylene ATP (Table 4).
  • Suramin andpyridoxalphosphate-6-azophenyl-2',4'-disulfonic acid (PPADS) are examples of non-specific antagonists.
  • homology and identity mean the same thing as similarity.
  • the use of the word homology is used between two non-natural sequences it is understood that this is not necessarily indicating an evolutionary relationship between these two sequences, but rather is looking at the similarity or relatedness between their nucleic acid sequences.
  • Many of the methods for determining homology between two evolutionarily related molecules are routinely applied to any two or more nucleic acids or proteins for the pu ⁇ ose of measuring sequence similarity regardless of whether they are evolutionarily related or not.
  • SEQ ID NO:l represents a version of a P2X receptor. All fragments of the P2X receptor, as well as the other proteins, such as receptors discussed herein, are considered disclosed.
  • variants of genes and proteins herein disclosed typically have at least, about 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, or 99 percent homology to the stated sequence or the native sequence.
  • the homology can be calculated after aligning the two sequences so that the homology is at its highest level. Another way of calculating homology can be performed by published algorithms. Optimal alignment of sequences for comparison can be conducted by the local homology algorithm of Smith and Waterman Adv.
  • a sequence recited as having a particular percent homology to another sequence refers to sequences that have the recited homology as calculated by any one or more of the calculation methods described above.
  • a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using the Zuker calculation method even if the first sequence does not have 80 percent homology to the second sequence as calculated by any of the other calculation methods.
  • a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using both the Zuker calculation method and the Pearson and Lipman calculation method even if the first sequence does not have 80 percent homology to the second sequence as calculated by the Smith and Waterman calculation method, the Needleman and Wunsch calculation method, the Jaeger calculation methods, or any of the other calculation methods.
  • a first sequence has 80 percent homology, as defined herein, to a second sequence if the first sequence is calculated to have 80 percent homology to the second sequence using each of calculation methods (although, in practice, the different calculation methods will often result in different calculated homology percentages).
  • hybridization typically means a sequence driven interaction between at least two nucleic acid molecules, such as a primer or a probe and a gene.
  • Sequence driven interaction means an interaction that occurs between two nucleotides or nucleotide analogs or nucleotide derivatives in a nucleotide specific manner. For example, G interacting with C or A interacting with T are sequence driven interactions. Typically sequence driven interactions occur on the Watson-Crick face or Hoogsteen face of the nucleotide.
  • the hybridization of two nucleic acids is affected by a number of conditions and parameters known to those of skill in the art. For example, the salt concentrations, pH, and temperature of the reaction all affect whether two nucleic acid molecules will hybridize.
  • selective hybridization conditions can be defined as stringent hybridization conditions.
  • stringency of hybridization is controlled by both temperature and salt concentration of either or both of the hybridization and washing steps.
  • the conditions of hybridization to achieve selective hybridization can involve hybridization in high ionic strength solution (6X SSC or 6X SSPE) at a temperature that is about 12-25°C below the Tm (the melting temperature at which half of the molecules dissociate from their hybridization partners) followed by washing at a combination of temperature and salt concentration chosen so that the washing temperature is about 5°C to 20°C below the Tm.
  • the temperature and salt conditions are readily determined empirically in preliminary experiments in which samples of reference DNA immobilized on filters are hybridized to a labeled nucleic acid of interest and then washed under conditions of different stringencies. Hybridization temperatures are typically higher for DNA- RNA and RNA-RNA hybridizations. The conditions can be used as described above to achieve stringency, or as is known in the art. (Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, New York, 1989; Kunkel et al. Methods Enzymol. 1987:154:367, 1987 which is herein inco ⁇ orated by reference for material at least related to hybridization of nucleic acids).
  • a preferable stringent hybridization condition for a DNA:DNA hybridization can be at about 68°C (in aqueous solution) in 6X SSC or 6X SSPE followed by washing at 68°C.
  • Stringency of hybridization and washing if desired, can be reduced accordingly as the degree of complementarity desired is decreased, and further, depending upon the G-C or A-T richness of any area wherein variability is searched for.
  • stringency of hybridization and washing if desired, can be increased accordingly as homology desired is increased, and further, depending upon the G-C or A-T richness of any area wherein high homology is desired, all as known in the art.
  • selective hybridization is by looking at the amount (percentage) of one of the nucleic acids bound to the other nucleic acid.
  • selective hybridization conditions would be when at least about, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percent of the limiting nucleic acid is bound to the non-limiting nucleic acid.
  • the non-limiting primer is in for example, 10 or 100 or 1000 fold excess.
  • This type of assay can be performed at under conditions where both the limiting and non-limiting primer are for example, 10 fold or 100 fold or 1000 fold below their K ⁇ j > or where only one of the nucleic acid molecules is 10 fold or 100 fold or 1000 fold or where one or both nucleic acid molecules are above their K ⁇ j.
  • selective hybridization conditions would be when at least about, 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100 percent of the primer is enzymatically manipulated under conditions which promote the enzymatic manipulation, for example if the enzymatic manipulation is DNA extension, then selective hybridization conditions would be when at least about 60, 65, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90,
  • nucleic acid based there are a variety of molecules disclosed herein that are nucleic acid based, including for example the nucleic acids that encode, for example the purinergic receptors, as well as various functional nucleic acids.
  • the disclosed nucleic acids are made up of, for example, nucleotides, nucleotide analogs, or nucleotide substitutes. Non-limiting examples of these and other molecules are discussed herein. It is understood that for example, when a vector is expressed in a cell that the expressed mRNA will typically be made up of A, C, G, and U.
  • an antisense molecule is introduced into a cell or cell environment through for example exogenous delivery, it is advantageous that the antisense molecule be made up of nucleotide analogs that reduce the degradation of the antisense molecule in the cellular environment.
  • nucleotide is a molecule that contains a base moiety, a sugar moiety and a phosphate moiety.
  • Nucleotides can be linked together through their phosphate moieties and sugar moieties creating an intemucleoside linkage.
  • the base moiety of a nucleotide can be adenin-9-yl (A), cytosin-1-yl (C), guanin-9-yl (G), uracil-1-yl (U), and thymin-1-yl (T).
  • the sugar moiety of a nucleotide is a ribose or a deoxyribose.
  • the phosphate moiety of a nucleotide is pentavalent phosphate.
  • a non-limiting example of a nucleotide would be 3'-AMP (3'-adenosine monophosphate) or 5'-GMP (5'-guanosine monophosphate).
  • a nucleotide analog is a nucleotide, which contains some type of modification to the base, sugar, or phosphate moieties. Modifications to nucleotides are well known in the art and would include for example, 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, and 2-aminoadenine as well as modifications at the sugar or phosphate moieties. Nucleotide substitutes are molecules having similar functional properties to nucleotides, but which do not contain a phosphate moiety, such as peptide nucleic acid (PNA).
  • PNA peptide nucleic acid
  • Nucleotide substitutes are molecules that will recognize nucleic acids in a Watson-Crick or Hoogsteen manner, but which are linked together through a moiety other than a phosphate moiety. Nucleotide substitutes are able to conform to a double helix type structure when interacting with the appropriate target nucleic acid. It is also possible to link other types of molecules (conjugates) to nucleotides or nucleotide analogs to enhance for example, cellular uptake. Conjugates can be chemically linked to the nucleotide or nucleotide analogs. Such conjugates include but are not limited to lipid moieties such as a cholesterol moiety. (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989,86, 6553-6556),
  • a Watson-Crick interaction is at least one interaction with the Watson-Crick face of a nucleotide, nucleotide analog, or nucleotide substitute.
  • the Watson-Crick face of a nucleotide, nucleotide analog, or nucleotide substitute includes the C2, Nl, and C6 positions of a purine based nucleotide, nucleotide analog, or nucleotide substitute and the C2, N3, C4 positions of a pyrimidine based nucleotide, nucleotide analog, or nucleotide substitute.
  • a Hoogsteen interaction is the interaction that takes place on the Hoogsteen face of a nucleotide or nucleotide analog, which is exposed in the major groove of duplex DNA.
  • the Hoogsteen face includes the N7 position and reactive groups (NH2 or O) at the C6 position of purine nucleotides.
  • a nucleotide analog is a nucleotide, which contains some type of modification to the base, sugar, or phosphate moieties. Modifications to the base moiety would include natural and synthetic modifications of A, C, G, and T/U as well as different purine or pyrimidine bases, such as uracil-5-yl (.psi.), hypoxanthin-9-yl (I), and 2-aminoadenin-9-yl.
  • a modified base includes but is not limited to 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-thiouracil, 2-thiotl ⁇ ymine and 2-thioeytosine, 5-halouracil and cytosine, 5-propynyl uracil and cytosine, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and
  • Nucleotide analogs can also include modifications of the sugar moiety. Modifications to the sugar moiety would include natural modifications of the ribose and deoxy ribose as well as synthetic modifications. Sugar modifications include but are not limited to the following modifications at the 2' position: OH; F; 0-, S-, or N-alkyl; 0-, S-, or N-alkenyl; 0-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl can be substituted or unsubstituted Ci to C ⁇ 0 , alkyl or C 2 to C JO alkenyl and alkynyl.
  • 2' sugar modifications also include but are not limited to -0[(CH 2 ) n 0] m CH 3 , -0(CH 2 ) n OCH 3 , -0(CH 2 ) n NH 2 , - 0(CH 2 ) n CH 3 , -0(CH 2 ) n -ONH 2 , and -0(CH 2 ) n ON[(CH 2 ) n CH 3 )] 2 , where n and m are from 1 to about 10.
  • modifications at the 2' position include but are not limited to: to o lower alkyl, substituted lower alkyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH 3 , OCN, CI, Br, CN, CF,, OCF 3 , SOCH 3 , S0 2 CH 3 , ON0 2 , N0 2 , N 3 , NH 2 , heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving tire pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties.
  • Similar modifications can also be made at other positions on the sugar, particularly the 3' position of the sugar on the 3' terminal nucleotide or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide.
  • Modified sugars would also include those that contain modifications at the bridging ring oxygen, such as CH 2 and S.
  • Nucleotide sugar analogs can also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.
  • Modified phosphate moieties include but are not limited to those that can be modified so that the linkage between two nucleotides contains a phosphorothioate, chiral phosphorothioate, phosphorodithioate, phosphofriester, aminoalkylphosphotriester, methyl and other alkyl phosphonates including 3'-alkylene phosphonate and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, and boranophosphates.
  • these phosphate or modified phosphate linkage between two nucleotides can be through a 3 '-5' linkage or a 2'-5' linkage, and the linkage can contain inverted polarity such as 3'-5' to 5'-3' or 2'-5' to 5 -2'.
  • Various salts, mixed salts and free acid forms are also included.
  • nucleotide analogs need only contain a single modification, but can also contain multiple modifications within one of the moieties or between different moieties.
  • Nucleotide substitutes are molecules having similar functional properties to nucleotides, but which do not contain a phosphate moiety, such as peptide nucleic acid (PNA). Nucleotide substitutes are molecules that will recognize nucleic acids in a Watson-Crick or Hoogsteen manner, but which are linked together through a moiety other than a phosphate moiety. Nucleotide substitutes are able to conform to a double helix type structure when interacting with the appropriate target nucleic acid.
  • PNA peptide nucleic acid
  • Nucleotide substitutes are nucleotides or nucleotide analogs that have had the phosphate moiety and/or sugar moieties replaced. Nucleotide substitutes do not contain a standard phosphorus atom. Substitutes for the phosphate can be for example, short chain alkyl or cycloalkyl intemucleoside linkages, mixed heteroatom and alkyl or cycloalkyl intemucleoside linkages, or one or more short chain heteroatomic or heterocyclic intemucleoside linkages.
  • Numerous United States patents disclose how to make and use these types of phosphate replacements and include but are not limited to 5,034,506; 5,166,315; 5,185,444; 5,214,134; 5,216,141; 5,235,033; 5,264,562; 5,264,564; 5,405,938; 5,434,257; 5,466,677; 5,470,967; 5,489,677; 5,541,307; 5,561,225; 5,596,086; 5,602,240; 5,610,289; 5,602,240; 5,608,046; 5,610,289; 5,618,704; 5,623,070; 5,663,312; 5,633,360; 5,677,437; and 5,677,439, each of which is herein inco ⁇ orated by reference.
  • nucleotide substitute that both the sugar and the phosphate moieties of the nucleotide can be replaced, by for example an amide type linkage (aminoethylglycine) (PNA).
  • PNA aminoethylglycine
  • conjugates can be chemically linked to the nucleotide or nucleotide analogs.
  • conjugates include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., Proc. Natl. Acad. Sci. USA, 1989,86, 6553-6556), cholic acid (Manoharan et al., Bioorg. Med. Chem.
  • a thioether e.g., hexyl-S-tritylthiol (Manoharan et al., Ann. N.Y. Acad. Sci., 1992, 660, 306-309; Manoharan et al., Bioorg. Med. Chem. Let, 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., Nucl.
  • Acids Res., 1990, 18, 3777-3783 a polya ine or a polyethylene glycol chain (Manoharan et al., Nucleosides & Nucleotides, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., Tetrahedron Lett., 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., Biochim.
  • a Watson-Crick interaction is at least one interaction with the Watson-Crick face of a nucleotide, nucleotide analog, or nucleotide substitute.
  • the Watson-Crick face of a nucleotide, nucleotide analog, or nucleotide substitute includes the C2, Nl, and C6 positions of a purine based nucleotide, nucleotide analog, or nucleotide substitute and the C2, N3, C4 positions of a pyrimidine based nucleotide, nucleotide analog, or nucleotide substitute.
  • a Hoogsteen interaction is the interaction that takes place on the Hoogsteen face of a nucleotide or nucleotide analog, which is exposed in the major groove of duplex DNA.
  • the Hoogsteen face includes the N7 position and reactive groups (NH2 or O) at the C6 position of purine nucleotides.
  • compositions including primers and probes, which are capable of interacting with the purinergic receptors as disclosed herein.
  • the primers are used to support DNA amplification reactions.
  • the primers will be capable of being extended in a sequence specific manner.
  • Extension of a primer in a sequence specific manner includes any methods wherein the sequence and/or composition of the nucleic acid molecule to which the primer is hybridized or otherwise associated directs or influences the composition or sequence of the product produced by the extension of the primer.
  • Extension of the primer in a sequence specific manner therefore includes, but is not limited to, PCR, DNA sequencing, DNA extension, DNA polymerization, RNA transcription, or reverse transcription. Techniques and conditions that amplify the primer in a sequence specific manner are preferred.
  • the primers are used for the DNA amplification reactions, such as PCR or direct sequencing. It is understood that in certain embodiments the primers can also be extended using non-enzymatic techniques, where for example, the nucleotides or oligonucleotides used to extend the primer are modified such that they will chemically react to extend the primer in a sequence specific manner.
  • the disclosed primers hybridize with a purinergic receptor nucleic acid or region of the purinergic receptor nucleic acid or they hybridize with the complement of the purinergic receptor nucleic acid or complement of a region of the purinergic receptor nucleic acid. , d) Delivery of the compositions to cells
  • compositions and methods which can be used to deliver nucleic acids to cells, either in vitro or in vivo. These methods and compositions can largely be broken down into two classes: viral based delivery systems and non-viral based delivery systems.
  • the nucleic acids can be delivered through a number of direct delivery systems such as, electroporation, lipofection, calcium phosphate precipitation, plasmids, viral vectors, viral nucleic acids, phage nucleic acids, phages, cosmids, or via transfer of genetic material in cells or carriers such as cationic liposomes.
  • the disclosed nucleic acids can be in the form of naked DNA or RNA, or the nucleic acids can be in a vector for delivering the nucleic acids to the cells, whereby the encoding DNA or DNA or fragment is under the transcriptional regulation of a promoter, as would be well understood by one of ordinary skill in the art as well as enhancers.
  • the vector can be a commercially available preparation, such as an adenovirus vector (Quantum Biotechnologies, Inc. (Laval, Quebec, Canada).
  • vector delivery can be via a viral system, such as a refroviral vector system which can package a recombinant refroviral genome (see e.g., Pastan et al., Proc. Natl. Acad. Sci. U.S.A. 85:4486, 1988; Miller et al., Mol. Cell. Biol. 6:2895, 1986).
  • the recombinant refrovims can then be used to infect and thereby deliver to the infected cells nucleic acid encoding a broadly neutralizing antibody (or active fragment thereof).
  • the exact method of introducing the altered nucleic acid into mammalian cells is, of course, not limited to the use of refroviral vectors.
  • adenoviral vectors Mitsubishi et al., Hum. Gene Ther. 5:941-948, 1994
  • adeno-associated viral (AAV) vectors Goodman et al., Blood 84:1492-1500, 1994
  • lentiviral vectors Non-typed refroviral vectors
  • compositions and methods can be used in conjunction with any of these or other commonly used gene transfer methods.
  • the dosage for administration of adenovirus to humans can range from about 10 7 to 10 9 plaque forming units (pfu) per injection but can be as high as 10 12 pfu per injection (Crystal, Hum. Gene liter. 8:985-1001, 1997; Alvarez and Curiel, Hum. Gene Ther. 8:597-613, 1997).
  • a subject can receive a single injection, or, if additional injections are necessary, they can be repeated at six-month intervals (or other appropriate time intervals, as determined by the skilled practitioner) for an indefinite period and/or until the efficacy of the treatment has been established.
  • Parenteral administration of the nucleic acid or vector, if used, is generally characterized by injection.
  • Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution of suspension in liquid prior to injection, or as emulsions.
  • a more recently revised approach for parenteral administration involves use of a slow release or sustained release system such that a constant dosage is maintained. See, e.g., U.S. Patent No. 3,610,795, which is inco ⁇ orated by reference herein.
  • suitable formulations and various routes of administration of therapeutic compounds see, e.g., Remington: The Science and Practice of Pharmacy (19th ed.) ed. A.R. Gennaro, Mack Publishing Company, Easton, PA 1995.
  • Nucleic acids that are delivered to cells which are to be integrated into the host cell genome typically contain integration sequences. These sequences are often viral related sequences, particularly when viral based systems are used. These viral integration systems can also be inco ⁇ orated into nucleic acids which are to be delivered using a non-nucleic acid based system of deliver, such as a liposome, so that the nucleic acid contained in the delivery system can be come integrated into the host genome.
  • a non-nucleic acid based system of deliver such as a liposome
  • Non-nucleic acid based systems are known to those of skill in the art.
  • compositions can be delivered to the target cells in a variety of ways.
  • the compositions can be delivered through electroporation, or through lipofection, or through calcium phosphate precipitation.
  • the delivery mechanism chosen will depend in part on the type of cell targeted and whether the delivery is occurring for example in vivo or in vitro.
  • the compositions can comprise, in addition to the disclosed compositions or vectors for example, lipids such as liposomes, such as cationic liposomes (e.g., DOTMA, DOPE, DC-cholesterol) or anionic liposomes.
  • Liposomes can further comprise proteins to facilitate targeting a particular cell, if desired.
  • compositions comprising a compound and a cationic liposome can be administered to the blood afferent to a target organ or inhaled into the respiratory tract to target cells of the respiratory tract.
  • liposomes see, e.g., Brigham et al. Am. J. Resp. Cell. Mol. Biol. 1:95-100 (1989); Feigner et al.
  • the compound can be administered as a component of a microcapsule that can be targeted to specific cell types, such as macrophages, or where the diffusion of the compound or delivery of the compound from the microcapsule is designed for a specific rate or dosage.
  • delivery of the compositions to cells can be via a variety of mechanisms.
  • delivery can be via a liposome, using commercially available liposome preparations such as LIPOFECTIN, LIPOFECTAMF E (GBCO-BRL, Inc., Gaithersburg, MD), SUPERFECT (Qiagen, Inc. Hilden, Germany) and TRANSFECTAM (Promega Biotec, Inc., Madison, WI), as well as other liposomes developed according to procedures standard in the art.
  • the nucleic acid or vector can be delivered in vivo by electroporation, the technology for which is available from Genetronics, hic. (San Diego, CA) as well as by means of a SONOPORATION machine (ImaRx Pharmaceutical Co ⁇ ., Arlington, AZ).
  • the materials can be in solution, suspension (for example, inco ⁇ orated into microparticles, liposomes, or cells). These can be targeted to a particular cell type via antibodies, receptors, or receptor ligands.
  • the following references are examples of the use of this technology to target specific proteins to tumor tissue (Senter, et al., Bioconjugate Chem..2:447-451, (1991); Bagshawe, K.D., Br. J. Cancer. oughtministere
  • Vehicles such as "stealth” and other antibody conjugated liposomes (including lipid mediated drug targeting to colonic carcinoma), receptor mediated targeting of DNA tlirough cell specific ligands, lymphocyte directed tumor targeting, and highly specific therapeutic refroviral targeting of murine glioma cells in vivo.
  • the following references are examples of the use of this technology to target specific proteins to tumor tissue (Hughes et al., Cancer Research. 49:6214-6220, (1989); and Litzinger and Huang, Biochimica et Biophvsica Acta. 1104:179-187, (1992)).
  • receptors are involved in pathways of endocytosis, either constitutive or ligand induced.
  • receptors cluster in clathrin-coated pits, enter the cell via clathrin-coated vesicles, pass through an acidified endosome in which the receptors are sorted, and then either recycle to the cell surface, become stored intracellularly, or are degraded in lysosomes.
  • the intemalization pathways serve a variety of functions, such as nutrient uptake, removal of activated proteins, clearance of macromolecules, opportunistic entry of viruses and toxins, dissociation and degradation of ligand, and receptor-level regulation. Many receptors follow more than one intracellular pathway, depending on the cell type, receptor concentration, type of ligand, ligand valency, and ligand concentration. Molecular and cellular mechanisms of receptor-mediated endocytosis have been reviewed (Brown and Greene, DNA and Cell Biology 10:6, 399-409 (1991)).
  • compositions can be administered in a pharmaceutically acceptable carrier and can be delivered to the subject's cells in vivo and/or ex vivo by a variety of mechanisms well known in the art (e.g., uptake of naked DNA, liposome fusion, intramuscular injection of DNA via a gene gun, endocytosis and the like).
  • cells or tissues can be removed and maintained outside the body according to standard protocols well known in the art.
  • the compositions can be introduced into the cells via any gene transfer mechanism, such as, for example, calcium phosphate mediated gene delivery, electroporation, microinjection or proteoliposomes.
  • the transduced cells can then be infused (e.g., in a pharmaceutically acceptable carrier) or homotopically transplanted back into the subject per standard methods for the cell or tissue type. Standard methods are known for transplantation or infusion of various cells into a subject.
  • the nucleic acids that are delivered to cells typically contain expression-controlling systems.
  • the inserted genes in viral and refroviral systems usually contain promoters, and/or enhancers to help control the expression of the desired gene product.
  • a promoter is generally a sequence or sequences of DNA that function when in a relatively fixed location in regard to the transcription start site.
  • a promoter contains core elements required for basic interaction of RNA polymerase and transcription factors, and can contain upstream elements and response elements. ..,
  • Preferred promoters controlling transcription from vectors in mammalian host cells can be obtained from various sources, for example, the genomes of viruses such as: polyoma, Simian Virus 40 (SV40), adenovims, retroviruses, hepatitis-B vims and most preferably cytomegalovims, or from heterologous mammalian promoters, e.g. beta actin promoter.
  • viruses such as: polyoma, Simian Virus 40 (SV40), adenovims, retroviruses, hepatitis-B vims and most preferably cytomegalovims, or from heterologous mammalian promoters, e.g. beta actin promoter.
  • the early and late promoters of the SV40 vims are conveniently obtained as an SV40 restriction fragment which also contains the SV40 viral origin of replication (Fiers et al, Nature. 273: 113 (1978)).
  • Enhancer generally refers to a sequence of DNA that functions at no fixed distance from the transcription start site and can be either 5' (Laimins, L. et al., Proc. Natl. Acad. Sci. 78: 993 (1981)) or 3' (Lusky, M.L., et al., Mol.Cell Bio. 3:1108 (1983)) to the transcription unit.
  • enhancers can be within an infron (Banerji, J.L. et al., Cell 33:729 (1983)) as well as within the coding sequence itself (Osbome, T.F., et al., Mol. Cell Bio.4:1293 (1984)). They are usually between 10 and 300 bp in length, and they function in cis. Enhancers function to increase transcription from nearby promoters. Enhancers also often contain response elements that mediate the regulation of transcription. Promoters can also contain response elements that mediate the regulation of transcription. Enhancers often determine the regulation of expression of a gene.
  • enhancer sequences are now known from mammalian genes (globin, elastase, albumin, -fetoprotein and insulin), typically one will use an enhancer from a eukaryotic cell vims for general expression. Examples are the SV40 enhancer on the late side of the replication origin (bp 100-270), the cytomegalovims early promoter enhancer, the polyoma enhancer on the late side of the replication origin, and adenovims enhancers.
  • the promoter and/or enhancer can be specifically activated either by light or specific chemical events which trigger their function.
  • Systems can be regulated by reagents such as tetracycline and dexamethasone.
  • reagents such as tetracycline and dexamethasone.
  • irradiation such as gamma irradiation, or alkylating chemotherapy drugs.
  • the promoter and/or enhancer regions can act as a constitutive promoter and/or enhancer to maximize expression of the region of the transcription unit to be transcribed.
  • the promoter and/or enhancer region be active in all eukaryotic cell types, even if it is only expressed in a particular type of cell at a particular time.
  • a preferred promoter of this type is the CMV promoter (650 bases).
  • Other preferred promoters are SV40 promoters, cytomegalovims (full length promoter), and refroviral vector LTF.
  • GFAP glial fibrillary acetic protein
  • Expression vectors used in eukaryotic host cells can also contain sequences necessary for the termination of franscription which can affect mRNA expression. These regions are transcribed as polyadenylated segments in the untranslated portion of the mRNA encoding tissue factor protein. The 3' untranslated regions also include franscription termination sites. It is preferred that the franscription unit also contains a polyadenylation region. One benefit of this region is that it increases the likelihood that the transcribed unit will be processed and transported like mRNA.
  • the identification and use of polyadenylation signals in expression constructs is well established. It is preferred that homologous polyadenylation signals be used in the transgene constructs.
  • the polyadenylation region is derived from the SV40 early polyadenylation signal and consists of about 400 bases. It is also preferred that the transcribed units contain other standard sequences alone or in combination with the above sequences improve expression from, or stability of, the construct.
  • the vectors can include nucleic acid sequence encoding a marker product. This marker product is used to determine if the gene has been delivered to the cell and once delivered is being expressed.
  • Preferred marker genes are the E. coli lacZ gene, which encodes ⁇ -galactosidase, and green fluorescent protein.
  • the marker can be a selectable marker.
  • suitable selectable markers for mammalian cells are dihydrofolate reductase (DHFR), thymidine kinase, neomycin, neomycin analog G418, hydromycin, and puromycin.
  • DHFR dihydrofolate reductase
  • thymidine kinase thymidine kinase
  • neomycin neomycin analog G418, hydromycin
  • puromycin puromycin.
  • selectable markers When such selectable markers are successfully transferred into a mammalian host cell, the fransformed mammalian host cell can survive if placed under selective pressure.
  • These cells lack the ability to grow without the addition of such nutrients as thymidine or hypoxanthine. Because these cells lack certain genes necessary for a complete nucleotide synthesis pathway, they cannot survive unless the missing nucleotides are provided in a supplemented media.
  • An alternative to supplementing the media is to introduce an intact DHFR or TK gene into cells lacking the respective genes, thus altering their growth requirements. Individual cells which were not transformed with the DHFR or TK gene will not be capable of survival in non-supplemented media. ,
  • the second category is dominant selection which refers to a selection scheme used in any cell type and does not require the use of a mutant cell line. These schemes typically use a d g to arrest growth of a host cell. Those cells which have a novel gene would express a protein conveying d g resistance and would survive the selection. Examples of such dominant selection use the d gs neomycin, (Southern P. and Berg, P.. J. Molec. Appl. Genet. 1:327 (1982)), mycophenolic acid, (Mulligan, R.C. and Berg, P. Science 209:1422 (1980)) or hygromycin, (Sugden, B. et al., Mol. Cell. Biol.
  • Protein variants and derivatives are well understood to those of skill in the art and in can involve amino acid sequence modifications.
  • amino acid sequence modifications typically fall into one or more of three classes: substitutional, insertional or deletional variants.
  • Insertions include amino and/or carboxyl terminal fusions as well as intrasequence insertions of single or multiple amino acid residues. Insertions ordinarily will be smaller insertions than those of amino or carboxyl terminal fusions, for example, on the order of one to four residues.
  • Immunogenic fusion protein derivatives are made by fusing a polypeptide sufficiently large to confer immunogenicity to the target sequence by cross-linking in vitro or by recombinant cell culture transformed with DNA encoding the fusion.
  • Deletions are characterized by the removal of one or more amino acid residues from the protein sequence. Typically, no more than about from 2 to 6 residues are deleted at any one site within the protein molecule.
  • These variants ordinarily are prepared by site-specific mutagenesis of nucleotides in the DNA encoding the protein, thereby producing DNA encoding the variant, and thereafter expressing the DNA in recombinant cell culture.
  • substitution mutations at predetermined sites in DNA having a known sequence are well known, for example Ml 3 primer mutagenesis and PCR mutagenesis.
  • Amino acid substitutions are typically of single residues, but can occur at a number of different locations at once; insertions usually will be on the order of about from 1 to 10 amino acid residues; and deletions will range about from 1 to 30 residues.
  • Deletions or insertions preferably are made in adjacent pairs, i.e. a deletion of 2 residues or insertion of 2 residues.
  • Substitutions, deletions, insertions or any combination thereof can be combined to arrive at a final construct.
  • the mutations must not place the sequence out of reading frame and preferably will not create complementary regions that could produce secondary mRNA structure.
  • Substitutional variants are those in which at least one residue has been removed and a different residue inserted in its place. Such substitutions generally are made in accordance with the following Tables 5 and 6 and are referred to as conservative substitutions.
  • substitutions that are less conservative than those in Table 6, i.e., selecting residues that differ more significantly in their effect on maintaining (a) the stracture of the polypeptide backbone in the area of the substitution, for example as a sheet or helical conformation, (b) the charge or hydrophobicity of the molecule at the target site or (c) the bulk of the side chain.
  • substitutions which in general are expected to produce the greatest changes in the protein properties will be those in which (a) a hydrophilic residue, e.g. seryl or threonyl, is substituted for (or by) a hydrophobic residue, e.g.
  • a residue having an elecfropositive side chain e.g., lysyl, arginyl, or histidyl
  • an electronegative residue e.g.
  • substitutional or deletional mutagenesis can be employed to insert sites for N-glycosylation (Asn-X- Thr/Ser) or O-glycosylation (Ser or Thr).
  • Deletions of cysteine or other labile residues also can be desirable.
  • Deletions or substitutions of potential proteolysis sites e.g. Arg
  • Arg is accomplished for example by deleting one of the basic residues or substituting one by glutaminyl or histidyl residues.
  • Certain post-franslational derivatizations are the result of the action of recombinant host cells on the expressed polypeptide. Glutaminyl and asparaginyl residues are frequently post-translationally deamidated to the corresponding glutamyl and asparyl residues. Alternatively, these residues are deamidated under mildly acidic conditions.
  • post-franslational modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the o-amino groups of lysine, arginine, and histidine side chains (T.E. Creighton, Proteins: Structure and Molecular Properties, W. H.
  • variants and derivatives of the disclosed proteins herein are through defining the variants and derivatives in terms of homology/identity to specific known sequences.
  • SEQ ID NO:l sets forth a particular sequence of a P2X receptor.
  • variants of these and other proteins herein disclosed which have at least, 70% or 75% or 80% or 85% or 90% or 95% homology to the stated sequence.
  • the homology can be calculated after aligning the two sequences so that the homology is at its highest level.
  • Another way of calculating homology can be performed by published algorithms. Optimal alignment of sequences for comparison can be conducted by the local homology algorithm of Smith and Waterman Adv.
  • nucleic acids can be obtained by for example the algorithms disclosed in Zuker, M. Science 244:48-52, 1989, Jaeger et al. Proc. Natl. Acad. Sci. USA 86:7706-7710, 1989, Jaeger et al. Methods Enzymol. 183:281-306, 1989 which are herein inco ⁇ orated by reference for at least material related to nucleic acid alignment.
  • nucleic acids that can encode those protein sequences are also disclosed. This would include all degenerate sequences related to a specific protein sequence, i.e. all nucleic acids having a sequence that encodes one particular protein sequence as well as all nucleic acids, including degenerate nucleic acids, encoding the disclosed variants and derivatives of the protein sequences. Thus, while each particular nucleic acid sequence cannot be written out herein, it is understood that each and every sequence is in fact disclosed and described herein through the disclosed protein sequence.
  • compositions such as the ATP and ATP analogs
  • pharmaceutically acceptable is meant a material that is not biologically or otherwise undesirable, i.e., the material can be administered to a subject, along with the nucleic acid or vector, without causing any undesirable biological effects or interacting in a deleterious manner with any of the other components of the pharmaceutical composition in which it is contained.
  • the carrier would naturally be selected to minimize any degradation of the active ingredient and to minimize any adverse side effects in the subject, as would be well known to one of skill in the art.
  • compositions can be administered orally, parenterally (e.g., intravenously), by intramuscular injection, by intraperitoneal injection, fransdermally, exfraco ⁇ oreally, topically or the like, including topical intranasal administration or administration by inhalant.
  • topical intranasal administration means delivery of the compositions into the nose and nasal passages tlirough one or both of the nares and can comprise delivery by a spraying mechanism or droplet mechanism, or through aerosolization of the composition.
  • Administration of the compositions by inhalant can be through the nose or mouth via delivery by a spraying or droplet mechanism. Delivery can also be directly to any area of the respiratory system (e.g., lungs) via intubation.
  • compositions required will vary from subject to subject, depending on the species, age, weight and general condition of the subject, the severity of the allergic disorder being treated, the particular nucleic acid or vector used, its mode of adminisfration and the like. Thus, it is not possible to specify an exact amount for every composition. However, an appropriate amount can be determined by one of ordinary skill in the art using only routine experimentation given the teachings herein.
  • Parenteral administration of the composition is generally characterized by injection.
  • Injectables can be prepared in conventional forms, either as liquid solutions or suspensions, solid forms suitable for solution of suspension in liquid prior to injection, or as emulsions.
  • a more recently revised approach for parenteral adminisfration involves use of a slow release or sustained release system such that a constant dosage is maintained. See, e.g., U.S. Patent No. 3,610,795, which is inco ⁇ orated by reference herein.
  • the materials can be in solution, suspension (for example, inco ⁇ orated into microparticles, liposomes, or cells). These can be targeted to a particular cell type via antibodies, receptors, or receptor ligands.
  • the following references are examples of the use of this technology to target specific proteins to tumor tissue (Senter, et al, Bioconjugate Chem.. 2:447-451, (1991); Bagshawe, K.D., Br. J. Cancer. 60:275- 281, (1989); Bagshawe, et al., Br. J. Cancer. 58:700-703, (1988); Senter, et al., Bioconiueate Chem.. 4:3-9, (1993); Battelli, et al., Cancer Immunol.
  • Vehicles such as "stealth” and other antibody conjugated liposomes (including lipid mediated drag targeting to colonic carcinoma), receptor mediated targeting of DNA through cell specific ligands, lymphocyte directed tumor targeting, and highly specific therapeutic refroviral targeting of murine glioma cells in vivo.
  • stealth and other antibody conjugated liposomes (including lipid mediated drag targeting to colonic carcinoma), receptor mediated targeting of DNA through cell specific ligands, lymphocyte directed tumor targeting, and highly specific therapeutic refroviral targeting of murine glioma cells in vivo.
  • receptors are involved in pathways of endocytosis, either constitutive or ligand induced. These receptors cluster in clathrin-coated pits, enter the cell via clathrin-coated vesicles, pass through an acidified endosome in which the receptors are sorted, and then either recycle to the cell surface, become stored infracellularly, or are degraded in lysosomes.
  • the internalization pathways serve a variety of functions, such as nutrient uptake, removal of activated proteins, clearance of macromolecules, opportunistic entry of vimses and toxins, dissociation and degradation of ligand, and receptor-level regulation. Many receptors follow more than one intracellular pathway, depending on the cell type, receptor concentration, type of ligand, ligand valency, and ligand concentration. Molecular and cellular mechanisms of receptor-mediated endocytosis have been reviewed (Brown and Greene, DNA and Cell Biology 10:6, 399-409 (1991)).
  • Suitable carriers and their formulations are described in Remington: The Science and Practice of Pharmacy (19th ed.) ed. A.R. Gennaro, Mack Publishing Company, Easton, PA 1995.
  • an appropriate amount of a pharmaceutically-acceptable salt is used in the fomiulation to render the formulation isotonic.
  • the pharmaceutically-acceptable carrier include, but are not limited to, saline, Ringer's solution and dextrose solution.
  • the pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5.
  • Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to those persons skilled in the art that certain carriers can be more preferable depending upon, for instance, the route of adminisfration and concentration of composition being administered.
  • compositions can be administered intramuscularly or subcutaneously. Other compounds will be administered according to standard procedures used by those skilled in the art.
  • compositions can include carriers, thickeners, diluents, buffers, preservatives, surface- active agents and the like in addition to the molecule of choice.
  • Pharmaceutical compositions can also include one or more active ingredients such as antimicrobial agents, antiinflammatory agents, anesthetics, and the like.
  • the pharmaceutical composition can be administered in a number of ways depending on whether local or systemic treatment is desired, and on the area to be treated. Administration can be topically (including ophthalmically, vaginally, rectally, intranasally), orally, by inhalation, or parenterally, for example by intravenous drip, subcutaneous, infraperitoneal or intramuscular injection.
  • the disclosed antibodies can be administered intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally.
  • Preparations for parenteral adminisfration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
  • non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate.
  • Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media.
  • Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils.
  • Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives can also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, and inert gases and the like.
  • Formulations for topical adminisfration can include ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders.
  • Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like can be necessary or desirable.
  • compositions for oral administration include powders or granules, suspensions or solutions in water or non-aqueous media, capsules, sachets, or tablets. Thickeners, flavorings, diluents, emulsifiers, dispersing aids or binders can be desirable.
  • compositions can potentially be administered as a pharmaceutically acceptable acid- or base- addition salt, fonned by reaction with inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid, and organic acids such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succmic acid, maleic acid, and fumaric acid, or by reaction with an inorganic base such as sodium hydroxide, ammonium hydroxide, potassium hydroxide, and organic bases such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid
  • organic acids such as formic acid, acetic acid, propionic acid
  • Effective dosages and schedules for administering the compositions can be determined empirically, and making such determinations is within the skill in the art.
  • the dosage ranges for the adminisfration of the compositions are those large enough to produce the desired effect in which the symptoms of the disorder are affected.
  • the dosage should not be so large as to cause adverse side effects, such as unwanted cross-reactions, anaphylactic reactions, and the like.
  • the dosage will vary with the age, condition, sex and extent of the disease in the patient, route of adminisfration, or whether other dmgs are included in the regimen, and can be determined by one of skill in the art.
  • the dosage can be adjusted by the individual physician in the event of any counterindications.
  • Dosage can vary, and can be administered in one or more dose administrations hourly or daily,for one or several days.
  • Guidance can be found in the literature for appropriate dosages for given classes of pharmaceutical products.
  • guidance in selecting appropriate doses for antibodies can be found in the literature on therapeutic uses of antibodies, e.g., Handbook of Monoclonal Antibodies, Ferrone et al., eds., Noges Publications, Park Ridge, N.J., (1985) ch. 22 and pp. 303-357; Smith et al., Antibodies in Human Diagnosis and Therapy, Haber et al., eds., Raven Press, New York (1977) pp. 365-389.
  • _town ⁇ daily dosage of the ATP or ATP analogs used alone might range from about 1 ⁇ g/kg to up to 100 mg kg of body weight or more per day, depending on the factors mentioned above. For example, based on the similarities of EC 50 concentrations for P2 receptors across many species an effective dose to modulate smell in a human would be similar to our mouse model, i.e., 10-200 ⁇ M. Following administration of a disclosed composition, such as an ATP analog, for the modulation of smell, the efficacy of the therapeutic composition can be assessed in various ways well known to the skilled practitioner.
  • compositions disclosed herein are efficacious in modulating, such as enhancing or reducing the sensation of smell in a subject, by observing that the composition reduces or enhances the sensation of smell to a particular or general odor stimulant.
  • Smell sensation can be measured by methods that are known in the art, for example, and in vifro methods using an ORN calcium imaging assay as discussed herein, can also be used.
  • compositions that modulate smell disclosed herein can be administered prophylactically to patients or subjects who are at risk for being exposed to severe or damaging odor stimulation or who have a desire to have either an increased or decreased sensitivity to an odor.
  • elderly people can increase sensitivity to odor to compensate for loss during aging.
  • those on chemotherapy drags may need decreased odor sensitivity to reduce nausea.
  • nucleic acids and proteins and compositions can be represented as a sequence consisting of the nucleotides of amino acids. There are a variety of ways to display these sequences, ' for example the nucleotide guanosine can be represented by G or g. Likewise the amino acid valine can be represented by Val or V. Those of skill in the art understand how to display and express any nucleic acid or protein sequence in any of the variety of ways that exist, each of which is considered herein disclosed.
  • chips where at least one address is the sequences or part of the sequences set forth in any of the nucleic acid sequences disclosed herein. Also disclosed are chips where at least one address is the sequences or portion of sequences set forth in any of the peptide sequences disclosed herein. Disclosed are chips where at least one address is the composition, such as an ATP analog, disclosed herein.
  • chips where at least one address is a variant of the sequences or part of the sequences set forth in any of the nucleic acid sequences disclosed herein. Also disclosed are chips where at least one address is a variant of the sequences or portion of sequences set forth in any of the peptide sequences disclosed herein. j) Kits
  • kits that are drawn to reagents that can be used in practicing the methods disclosed herein.
  • the kits can include any reagent or combination of reagent discussed herein or that would be understood to be required or beneficial in the practice of the disclosed methods.
  • the kits could include an ATP analog in a formulation for delivery to an ORN.
  • a kit for modulating odor sensitivity comprising ATP in a formulation for delivery to an ORN.
  • compositions disclosed herein and the compositions necessary to perform the disclosed methods can be made using any method known to those of skill in the art for that particular reagent or compound unless otherwise specifically noted.
  • the disclosed ATP analogs can be made using a variety of synthetic procedures. Often the analogs can be purchased. For example, the following analogs can be purchased from Sigma Inc., 2-
  • nucleic acid synthesis the nucleic acids, such as, the oligonucleotides to be used as primers can be made using standard chemical synthesis methods or can be produced using enzymatic methods or any other known method. Such methods can range from standard enzymatic digestion followed by nucleotide fragment isolation (see for example, Sambrook et al, Molecular Cloning: A Laboratory Manual, 2nd Edition (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1989) Chapters 5, 6) to purely synthetic methods, for example, by the cyanoethyl phosphoramidite method using a Milligen or Beckman System IPlus DNA synthesizer (for example, Model 8700 automated synthesizer of Milligen-Biosearch, Burlington, MA or ABI Model 380B).
  • a Milligen or Beckman System IPlus DNA synthesizer for example, Model 8700 automated synthesizer of Milligen-Biosearch, Burlington, MA or ABI Model 380B.
  • compositions can be used in a variety of ways as research tools.
  • the disclosed compositions such as ATP and analogs, can be used to study the signal transduction pathways related to olfactory signaling.
  • compositions can be used as discussed herein as either reagents in micro arrays or as reagents to probe or analyze existing microarrays.
  • the compositions can also be used in any known method of screening assays, related to chip/micro arrays.
  • the compositions can also be used in any known way of using the computer readable embodiments of the disclosed compositions, for example, to study relatedness or to perform molecular modeling analysis related to the disclosed compositions. a) Screening assays
  • kits for screening for an agonist or an antagonist of purinergic receptor of the olfactory system comprising contacting a purinergic receptor with a test compound; detecting intracellular calcium levels; and screening for a change in calcium levels as compared to a control level, a change indicating the compound is an agonist or an antagonist of the olfactory system.
  • Multi-well plates are standard in the art and come in a variety of sizes and shapes.
  • the multi-well plate can be 24, 48, or 96 well plates.
  • Such screening assays can be automated or further modified for high throughput analysis.
  • each well can include numerous test components. If a positive reaction is detected in a well, the screening is repeated with one of the test compounds contained in a single well.
  • An “elevation in calcium” is defined as an increase in calcium levels greater than 1 nM above basal levels.
  • the change in calcium levels can be between 5 nM and 10 nM, for example.
  • the elevation in calcium can also be greater than 100 nM above basal levels.
  • a “transient reduction in calcium” is defined as decrease in calcium levels greater than 1 nM below basal levels.
  • the reduction in calcium can also be greater than 100 nM below basal levels.
  • fransient means not permanent.
  • fransient can be less than 10 seconds, less than 30 seconds, less than 1 minute, less than 5 minutes, less than 10 minutes, or less than 20 minutes, for example.
  • sustained means that the effect continues for a period of tim.
  • sustained can be greater than 1 minute, greater than 5 minutes, greater than 10 minutes, greater than an hour, greater than 24 hours, or greater than 1 year.
  • Also disclosed is a method of screening for an agonist or an antagonist of a purinergic receptor of the olfactory system comprising contacting a first purinergic receptor expressing cell with a set of test compounds; detecting calcium levels in the first purinergic receptor cell; and selecting each compound in the set that contacted the first purinergic receptor cell, wherein the first purinergic receptor cell showed a fransient change in calcium as compared to a control level, indicating the compound is an agonist or an antagonist of a purinergic receptor of the olfactory system.
  • the method can further comprise the steps of contacting a second purinergic receptor cell with one test compound selected above, and detecting calcium levels in the second purinergic receptor cell, wherein a fransient change in calcium as compared to a control level indicates the compound is an agonist or an antagonist of a purinergic receptor of the olfactory system.
  • Also disclosed is a method of screening for an agonist or an antagonist of a purinergic receptor of the olfactory system comprising contacting a test compound with a cell that expresses a heterologous nucleic acid that encodes a purinergic receptor; and detecting calcium levels in the cell; a transient change in calcium as compared to a control level, indicating an agonist or an antagonist of a purinergic receptor of the olfactory system.
  • agents identified by the screening methods described herein as well as methods of making those agents.
  • An example of a method of making an agent includes identifying the agent using the methods provided herein, and manufacturing the agent or manufacturing the agent in a pharmaceutically acceptable carrier.
  • the cell is a cell that lacks the receptor prior to introduction of the heterologous nucleic acid.
  • the cell can be transiently transfected with the heterologous nucleic acid or a stable cell line containing the expressed receptor can be made using standard techniques in the art.
  • heterologous nucleic acid is meant that any heterologous or exogenous nucleic acid can be inserted into a vector for transfer into a cell, tissue or organism.
  • the nucleic acid can encode a polypeptide or protein or an antisense RNA, for example.
  • the nucleic acid can be functionally linked to a promoter.
  • the promoter can promote expression of the heterologous nucleic acid, as is known in the art, such as appropriate orientation of the promoter relative to the heterologous nucleic acid.
  • the heterologous nucleic acid preferably has all appropriate sequences for expression of the nucleic acid, as known in the art, to functionally encode, i.e., allow the nucleic acid to be expressed.
  • the nucleic acid can include, for example, expression control sequences, such as an enhancer, and necessary information processing sites, such as ribosome binding sites, RNA splice sites, polyadenylation sites, and franscriptional terminator sequences.
  • Calcium levels and changes in calcium levels can be detected using a calcium indicator such as the cell-permeable methyl ester form of Fura-2, which is Fura-2/AM.
  • a fluorescence plate reader is used that detects a single wavelength, such as Ca 2+ indicator dyes Fluo 3, Fluo 4 AM, Quin 2, Indo-1 and ft ⁇ do-4.
  • the compound being screened can augment the effects of other compounds such as ATP, for example.
  • the compound being screened can be tested in the presence of another compound that stimulates the purinergic receptor.
  • the purinergic receptor expressing cell can be in a solution containing an effective amount of ATP.
  • An "effective amount of ATP" is defined as about 300 nM to about 1 mM of ATP. F. Examples
  • RT-PCR and immunohistochemical methods ionotropic P2X 2 and G-protein-coupled P2Y 2 receptor expression were found in both olfactory epithelium and olfactory bulb.
  • RT-PCR analysis revealed mRNA expression for the P2Y 2 receptor and two isoforms of the P2X 2 receptor; P2X 2 .j (Brake, A. J., et al., Nature 371, 519-523 (1994)) and P2X 2 . 2 (Brandle et al., 1997) (Fig. IA).
  • OMP-positive ORNs showed punctate immunoreactivity (IR) to P2Xj and P2X antibodies on cell somas and axons (Fig. IB, C) and P2Y 2 -IR on the dendrites, somas and axons (Fig. ID). Both P2X- and P2Y-IR was absent from dendritic knobs and cilia of ORNs.
  • OMP-negative ORNs and basal cells showed P2X- and P2Y-IR.
  • Sustentacular cells and Bowman's glands showed only P2Y 2 -IR (Fig ID).
  • P2X, P2X 2 , P2X 4 and P2Y 2 receptor IR in the olfactory nerve layer, the glomeralar layer and the mitral cell layer.
  • P2X 2 -IR there was no P2X 2 -IR in the olfactory neuroepithelium; however, there was punctate P2X 2 -IR on blood vessels just below the basal cells.
  • the underlying blood vessels are the likely source of P2X 2 mRNA identified by the RT-PCR studies of the olfactory epithelium.
  • Preabso ⁇ tion of the primary antibody with peptide antigen (Fig. IE) or omission of the primary antibody blocked the purinergic receptor staining.
  • Identification of regionally localized purinergic receptors in mammalian olfactory epithelium is consistent with extracellular ATP playing multiple roles in the peripheral olfactory system.
  • purinergic receptor agonists were used. As there are no completely specific purinergic receptor agonists (Ralevic and Burnstock, 1998), the selectivity was determined as discussed herein.
  • the P2X 'selective' agonist ⁇ -methylene ATP was superfused onto the slice (Fig. 3C). Only the ORNs, and not the sustentacular cells, responded to ⁇ -methylene ATP with an increase in [Ca 2+ ]j (Fig. 3C5).
  • the P2Y 'selective' agonist UTP evoked calcium transients in both ORNs and sustentacular cells (Fig. 3D).
  • adenosine receptor 'selective' agonist (UTP, ADP, MeS-ADP), P2X-'selective' agonists ( ⁇ -methylene ATP) (Fig. 4A, B), and an adenosine receptor 'selective' agonist (adenosine) were superfused onto olfactory epithelial slices and the change in [Ca 2+ ], was measured. Adenosine- or AMP-evoked calcium transients were never observed. ORNs responded with approximately equal frequency to P2Y and P2X receptor agonists whereas sustentacular cells responded primarily to P2Y receptor agonists.
  • PPADS 25 ⁇ M
  • Purinergic receptor antagonists also reversibly blocked purinergic nucleotide-evoked calcium transients in sustentacular cells.
  • the data show that the ATP-evoked calcium fransients were mediated by P2X and P2Y receptors. (4) ATP Modulates Odor Responses
  • ⁇ -methylene ATP like ATP, enhanced the odor responsiveness due to the activation of P2X receptors in a few cells.
  • the P2X specific agonist significantly reduced odor-induced Ca 2+ transients.
  • purinergic receptor subtypes are differentially expressed in ORNs and sustentacular cells, and ORNs express multiple purinergic receptor subtypes.
  • expression of more than one type of purinergic receptor allows for regulation of multiple effectors and modification of agonist-evoked responses, and provides a mechanism for rapid and local fine tuning at the cellular level (Ralevic and Burnstock, 1998).
  • Disclosed immunohistochemical studies showed a notable absence of purinergic receptors in the dendritic knobs and cilia, the site of odor transduction, whereas both P2X and P2Y receptors are located on cell somas and other regions.
  • Primers for detection of P2X 2 transcripts were 756-775 sense and 1537-1558 antisense oligonucleotides (accession #U14414)(Brake et al., 1994), primers for P2Y 2 transcripts were 1288- 1307 sense and 1931-1950 antisense oligonucleotides (accession #U09402), primers for ⁇ -actin transcripts (Lopez-Candales et al., 1995) were 1038-1067 sense and 1875-1905 antisense oligonucleotides and primers for neuron specific enolase were 348-368 sense and 1101-1123 antisense oligonucleotides (accession #M11931).
  • PCR protocol was used for detection of the P2X 2 receptor transcript. PCR products were excised from the gel and reamplified for 28 cycles using the same antisense primer and a sense primer corresponding to position 1059-1078. PCR products were sequenced at the University of Utah Sequencing Center.
  • mice postnatal day 0-6 were quickly decapitated, and the skin and lower jaw were removed. Tissue was mounted in ice cold Ringers onto a vibratome-cutting block and 300 ⁇ m slices were made. Primary cultures of mouse ORNs were made using the same protocol and culture conditions as described for rat olfactory receptor neurons (Vargas and Lucero, 1999a). Briefly, tissue was placed in divalent cation-free Ringers containing 10 mg/ml bovine semm albumin, 1 mg/ml deoxyribonuclease II and 44 U/ml dispase, incubated at 37°C for 45 min.
  • tissue was washed, triturated, and filtered tlirough a 53 mm mesh and 200 ml cells were plated onto concanavalin A-coated coverslips and allowed to settle for 20 min.
  • An additional 1.5 ml of culture medium was added (DMEM supplemented with 100 mM ascorbic acid, IX insulin-transferrin-seleniumX (GIBCO BRL), 2 mM glutamine, 100 U/ml penicillin G and 100 mg/ml streptomycin).
  • DMEM supplemented with 100 mM ascorbic acid, IX insulin-transferrin-seleniumX (GIBCO BRL), 2 mM glutamine, 100 U/ml penicillin G and 100 mg/ml streptomycin.
  • Electrodes (2 -5 M ⁇ ) were filled with TMA-oxide internal solution (in mM: 62.5 TMA oxide, 62.5 KH 2 P0 4) 15 KCl, 5 MgCl 2; 11 EGTA, 10 HEPES, 1 glutathione, 5 TEA, 0.03% pluronic acid F-127, 0.3% DMSO, 150 mg/ml nystatin, pH 7.2, 330 mOsm).
  • Electro-olfactogram and on-cell recordings Slices of P0-P6 mouse OE were prepared as described above and mounted in a perfusion chamber with a bath flow of 3 ml/min. Test chemicals were introduced using a rotary injection valve (Rheodyne, Cotati, CA).
  • the electro-olfactogram (EOG) recording elecfrode (3 M NaCl fnl%agar; tip diameter, 5-10 mn) was positioned along the dorsal portion of the nasal septum.
  • the differential electrode (identical to the recording elecfrode) was positioned over skull cartilage and an Ag AgCU ground elecfrode was connected to the bath solution via a 3 M KCl agar bridge.
  • Responses to test agents were amplified (5000 X gain) and filtered (2 kHz) by a low-noise differential DC amplifier. Data was digitized (100 Hz) using Axoscope 8.0 software (Axon Instruments).
  • the recording elecfrode (5-8 M_ resistance) contained Ringer's solution. Test solutions were selected using a rotary valve and delivered for 30 sec using gravity flow. The time course of solution delivery was determined by placing an elecfrode in a slice and switching from Ringer's solution to distilled water. There was a 3 sec delay to initial electrical response, which peaked at 10 sec. The shaded region in Figure 8 shows the 30 sec window of when the valve was switched on and off.
  • the electrode was lowered into the dorsal septal region of the slice and a seal (0.5-1 Gohms) was made in voltage-clamp before switching to currentclamp with zero applied current. Only cells with a stable baseline were used. There was a 7 min wash between each test application. Experiments were conducted on 65 cells in 42 slices obtained from 14 P0-P6 mice from three litters. Only three cells survived long enough to complete the recovery portion of the >27 min protocol.
  • Example 3 ATP Reduces Cyclic Nucleotide-Induced Electrical Responses
  • Odor activation of G-protein-coupled receptors results in increased cAMP production, opening of cyclic nucleotide-gated channels, influx of Ca 2+ andNa + , depolarization of the membrane, and activation of voltage- and Ca 2+ -gated ion channels (Schild and Resfrepo, 1998).
  • purinergics can reduce the odor-evoked electrical activity of ORNs. Recording odor-evoked membrane responses from single ORNs has a low probability of success because each ORN expresses only one or a few odorant receptors (Buck and Axel, 1991).
  • a mixture of cyclic nucleotide modulators were used to record membrane responses: IBMX (100 ⁇ M), a phosphodiesterase inhibitor that prevents the breakdown of cAMP, CPT-cAMP (50 ⁇ M), and 8-Br-cGMP (50 ⁇ M), both membrane-permeant analogs of cAMP and cGMP, respectively.
  • This cyclic nucleotide mixture was tested initially to verify that it evoked membrane potential changes in the OE slice preparation.
  • the EOG measures field potential changes across the OE after stimulation. Similar EOG responses were obtained from both odor (10 ⁇ M) and the cyclic nucleotide mixture (Fig. 13 A), validating the replacement of odor with the mixture in subsequent recordings.
  • SEQ ID NO:l The following is the sequence for H.sapiens mRNA for ATP receptor P2X1 (accession number X83688). Other sequences have been published for P2X1 receptors from rat vas deferens (accession number X80477) and mouse urinary bladder (accession number X84896). 1 gaattcggct gatcccgcgg caggtgctag caggagctgg cagcatgggc tccccagggggg
  • SEQ ID NO:2 The following is the sequence for H.sapiens protein for ATP receptor P2X1 (accession number X83688). ARRFQEE AAFLFEYDTPR VLVR KKVGVIFRLIQLVVLVYV
  • SEQ ID NO:3 The following sequence for the P2X2 receptor is derived from rat PC12 cells (accession number U14414). Other sequences have been published for P2X2 receptors from rat cerebellum (accession number Y09910)
  • SEQ ID NO:4 The following sequence for the P2X2 receptor is derived from rat
  • PC12 cells accession number U14414 protein sequence.
  • SEQ ID NO: 5 The following sequence for the P2X3 receptor is derived from H.sapiens (accession number Y07683). Other sequences have been published for P2X3 receptors from rat dorsal root ganglion (accession number X91167 and X90651).
  • SEQ ID NO:7 The following sequence for the P2X4 receptor is derived from H.sapiens (accession number Y07684). Other sequences have been published for P2X4 receptors from rat brain (accession number X93565, U32497, X91200 and X87763) and rat pancreatic islet (accession number U47031).
  • SEQ ID NO:8 The following sequence for the P2X4 receptor is derived from H.sapiens (accession number Y07684) Protein sequence.
  • SEQ ID NO: 9 The following sequence for the P2X5 receptor is derived from H.sapiens (accession number AF016709). Other sequences have been published for P2X5 receptors from rat brain (accession number X92069) and rat heart (accession number X97328).
  • SEQ ID NO:10 The following sequence for the P2X5 receptor is derived from H.sapiens (accession number AF016709) protein sequence.
  • H.sapiens (accession number AF065385). Other sequences have been published for P2X6 receptors from rat brain (accession numbers X92070 and X97376).
  • SEQ ID NO:12 The following sequence for the P2X6 receptor is derived from H.sapiens (accession number AF065385) protein sequence.
  • SEQ H The following sequence for the P2X7 receptor is derived from H.sapiens brain (accession number Y09561). Please note that other sequences have been published for P2X7 receptors from rat brain (accession numbers X95882)
  • 361 aaggccaaga gcagcggttg tgtcccgagt atcccacccg caggacgctc tgttcctctg
  • SEQ ID NO:14 The following sequence for the P2X7 receptor is derived from H.sapiens brain (accession number Y09561) protein sequence
  • SEQ ID NO:15 The following sequence for the P2Y1 receptor is derived from H.sapiens (accession number S81950). Other sequences have been published for P2Y1 receptors from human placenta (accession number Z49205), HEL cells (accession number U42030), bovine endothelium (accession numberX87628), rat cells (accession numbers U22830 and U22829), turkey brain (accession number U09842) and chicken brain (accession number X73268).
  • SEQ ID NO:16 The following sequence for the P2Y1 receptor is derived from H.sapiens (accession number S81950).
  • SEQ ID NO:17 The following sequence for the P2Y2 receptor is derived from H.sapiens epithelial cells (accession number U07225). Other sequences have been published for P2Y2 receptors from rat alveolar cells (accession number U09402), rat pituitary cells (accession number L46865), Wistar Kyoto rat (accession number
  • H.sapiens epithelial cells (accession number U07225) protein sequence.
  • SEQ ID NO:20 The following sequence for the P2y3 receptor is derived from chick brain (accession number X98283) protein sequence.
  • SEQ ID NO:21 The following sequence for the P2Y4 receptor is derived from H.sapiens (accession number X91852). Other sequences have been published for P2Y4 receptors from human chromosome X (accession number U40223), and rat heart (accession number Y14705).
  • SEQ ID NO:22 The following sequence for the P2Y4 receptor is derived from H.sapiens (accession number X91852) Protein sequence.
  • VFVLG GLNAPTL FIFRLRPWDATATYMFH A SDTLYV SLPTLIYYYAAHNH P FGTE I CKFVRF FYWN YCS VLFLTCI S VHRYLGI CHPLRA RWGRPRLAGLLCLAV LWAGC VPNLFFVTTSNKGTTV CHDTTRPEEFDHYVHFSSAVMGLLFGVPCLVT V CYGLi ARR YQP PGSAQSSSRLRS RTIAW TVFAVCFVPFHITRTIYYLARL EA DCRV NIV WYKVTRP ASANSCLDPVLYLLTGDKYRRQLRQLCGGGKPQPRTAASS LA VS PEDS S CR AATPQDS SCSTPRADRL
  • SEQ ID NO:23 The following sequence for the P2Y6 receptor is derived from H.sapiens placenta (accession numberX97058). Other sequences have been published for P2Y6 receptors from human placenta (accession number AF007893), and human activated T-cells (accession number U52464). W 2 .- ...
  • H.sapiens (accession number X91852) Protein sequence.
  • SEQ ID NO:24 The following sequence for the P2Y11 receptor is derived from human placenta (accession numberAF030335). Other sequences have been published for P2Y11 receptors from human HL-60 cells (accession number AJ298334).
  • the following sequence for the P2Y11 receptor is derived from human placenta (accession number AF030335) protein sequence.

Abstract

L'invention concerne des compositions et des procédés de modulation de la sensibilité aux odeurs, ainsi que des procédés de criblage permettant de détecter les composés modulant la sensibilité aux odeurs.
PCT/US2003/037389 2002-11-21 2003-11-21 Modulation purinergique d'odeur WO2004047749A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US10/535,774 US7557092B2 (en) 2002-11-21 2003-11-21 Purinergic modulation of smell
AT03789946T ATE542423T1 (de) 2002-11-21 2003-11-21 Purinerge geruchsmodulation
EP03789946A EP1624753B1 (fr) 2002-11-21 2003-11-21 Modulation purinergique d'odeur
AU2003294462A AU2003294462C1 (en) 2002-11-21 2003-11-21 Purinergic modulation of smell
CA002507044A CA2507044A1 (fr) 2002-11-21 2003-11-21 Modulation purinergique d'odeur

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42814002P 2002-11-21 2002-11-21
US60/428,140 2002-11-21

Publications (2)

Publication Number Publication Date
WO2004047749A2 true WO2004047749A2 (fr) 2004-06-10
WO2004047749A3 WO2004047749A3 (fr) 2004-10-21

Family

ID=32393355

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/037389 WO2004047749A2 (fr) 2002-11-21 2003-11-21 Modulation purinergique d'odeur

Country Status (6)

Country Link
US (1) US7557092B2 (fr)
EP (2) EP1624753B1 (fr)
AT (1) ATE542423T1 (fr)
AU (1) AU2003294462C1 (fr)
CA (1) CA2507044A1 (fr)
WO (1) WO2004047749A2 (fr)

Cited By (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005100990A2 (fr) * 2004-04-13 2005-10-27 Bayer Healthcare Ag Methodes diagnostiques et therapeutiques pour des maladies associees au purinocepteur 2 de type y (p2y2)
WO2006052007A1 (fr) * 2004-11-11 2006-05-18 Takeda Pharmaceutical Company Limited Agent de régulation de glycémie
WO2007042776A1 (fr) * 2005-10-07 2007-04-19 Imperial College Innovations Limited Modulateurs de la voie de signalisation purinergique pour traiter l'homeostasie du sodium, l'hypertension et l'hyperaldosteronisme
US7344860B2 (en) 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
EP2260858A2 (fr) 2003-11-06 2010-12-15 Seattle Genetics, Inc. Composés de monométhylvaline capable de conjugaison aux lignads.
WO2011000054A1 (fr) 2009-07-03 2011-01-06 Avipep Pty Ltd Immunoconjugués et leurs procédés de production
EP2286844A2 (fr) 2004-06-01 2011-02-23 Genentech, Inc. Conjugués anticorps-médicament et procédés
WO2011031870A1 (fr) 2009-09-09 2011-03-17 Centrose, Llc Conjugués médicamenteux ciblés à visée extracellulaire
WO2011056983A1 (fr) 2009-11-05 2011-05-12 Genentech, Inc. Conjugués d'anticorps modifiés par cystéine, radiomarqués par le zirconium
WO2011075786A1 (fr) 2009-12-23 2011-06-30 Avipep Pty Ltd Immuno-conjugués et leurs méthodes de production
WO2011130598A1 (fr) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazépines et conjugués de celles-ci
WO2011156328A1 (fr) 2010-06-08 2011-12-15 Genentech, Inc. Anticorps et conjugués modifiés par la cystéine
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
WO2012074757A1 (fr) 2010-11-17 2012-06-07 Genentech, Inc. Conjugués d'anticorps alaninyl-maytansinol
WO2012142662A1 (fr) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Molécules à domaine variable modifié et procédés de préparation et d'utilisation de celles-ci
WO2012155019A1 (fr) 2011-05-12 2012-11-15 Genentech, Inc. Procédé lc-ms/ms de surveillance de réactions multiples pour détecter des anticorps thérapeutiques dans des échantillons animaux à l'aide de peptides de signature d'infrastructure
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
WO2014057074A1 (fr) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazépines et leurs conjugués
WO2014140174A1 (fr) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazépines et leurs conjugués
WO2014140862A2 (fr) 2013-03-13 2014-09-18 Spirogen Sarl Pyrrolobenzodiazépines et leurs conjugués
WO2014159981A2 (fr) 2013-03-13 2014-10-02 Spirogen Sarl Pyrrolobenzodiazépines et leurs conjugués
WO2015023355A1 (fr) 2013-08-12 2015-02-19 Genentech, Inc. Conjugués anticorps-médicament dimérique 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
WO2015095227A2 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
WO2015095212A1 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés conjugués anticorps-médicament dimérique à base de 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
WO2015095223A2 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
WO2016037644A1 (fr) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
WO2016040825A1 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
WO2016040856A2 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Anticorps et conjugués modifiés génétiquement avec de la cystéine
WO2016090050A1 (fr) 2014-12-03 2016-06-09 Genentech, Inc. Composés d'amine quaternaire et conjugués anticorps-médicament de ceux-ci
EP3088004A1 (fr) 2004-09-23 2016-11-02 Genentech, Inc. Anticorps et conjugués modifiés au niveau des cystéines
WO2017059289A1 (fr) 2015-10-02 2017-04-06 Genentech, Inc. Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017064675A1 (fr) 2015-10-16 2017-04-20 Genentech, Inc. Conjugués médicamenteux à pont disulfure encombré
WO2017068511A1 (fr) 2015-10-20 2017-04-27 Genentech, Inc. Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
WO2017123633A1 (fr) * 2016-01-11 2017-07-20 Dignity Health Modulateurs des canaux cationiques activés par le zinc
WO2017165734A1 (fr) 2016-03-25 2017-09-28 Genentech, Inc. Dosage multiplexé pour la quantification d'anticorps totaux et de médicaments conjugués à des anticorps
EP3235820A1 (fr) 2014-09-17 2017-10-25 Genentech, Inc. Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
WO2017201449A1 (fr) 2016-05-20 2017-11-23 Genentech, Inc. Conjugués anticorps-protac et procédés d'utilisation
WO2017205741A1 (fr) 2016-05-27 2017-11-30 Genentech, Inc. Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site
WO2017214024A1 (fr) 2016-06-06 2017-12-14 Genentech, Inc. Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
WO2018031662A1 (fr) 2016-08-11 2018-02-15 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
US9919056B2 (en) 2012-10-12 2018-03-20 Adc Therapeutics S.A. Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9931415B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2018065501A1 (fr) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Procédés de préparation de conjugués anticorps-médicament
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10029018B2 (en) 2013-10-11 2018-07-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2019060398A1 (fr) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Analogues de thailanstatine
US10392393B2 (en) 2016-01-26 2019-08-27 Medimmune Limited Pyrrolobenzodiazepines
US10420777B2 (en) 2014-09-12 2019-09-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10543279B2 (en) 2016-04-29 2020-01-28 Medimmune Limited Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer
US10544223B2 (en) 2017-04-20 2020-01-28 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
WO2020049286A1 (fr) 2018-09-03 2020-03-12 Femtogenix Limited Amides polycycliques servant d'agents cytotoxiques
WO2020086858A1 (fr) 2018-10-24 2020-04-30 Genentech, Inc. Inducteurs chimiques conjugués de dégradation et méthodes d'utilisation
WO2020123275A1 (fr) 2018-12-10 2020-06-18 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
US10695439B2 (en) 2016-02-10 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
WO2020157491A1 (fr) 2019-01-29 2020-08-06 Femtogenix Limited Agents cytotoxiques de réticulation g-a
US10736903B2 (en) 2012-10-12 2020-08-11 Medimmune Limited Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US10799595B2 (en) 2016-10-14 2020-10-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2020227159A2 (fr) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
US11059893B2 (en) 2015-04-15 2021-07-13 Bergenbio Asa Humanized anti-AXL antibodies
US11135303B2 (en) 2011-10-14 2021-10-05 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2022023735A1 (fr) 2020-07-28 2022-02-03 Femtogenix Limited Agents cytotoxiques
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
US11352324B2 (en) 2018-03-01 2022-06-07 Medimmune Limited Methods
US11370801B2 (en) 2017-04-18 2022-06-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11517626B2 (en) 2016-02-10 2022-12-06 Medimmune Limited Pyrrolobenzodiazepine antibody conjugates
US11524969B2 (en) 2018-04-12 2022-12-13 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof as antitumour agents
US11612665B2 (en) 2017-02-08 2023-03-28 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US11649250B2 (en) 2017-08-18 2023-05-16 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11702473B2 (en) 2015-04-15 2023-07-18 Medimmune Limited Site-specific antibody-drug conjugates

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1624753B1 (fr) 2002-11-21 2012-01-25 The University of Utah Research Foundation Modulation purinergique d'odeur
CA2894961C (fr) 2012-12-21 2020-09-15 Spirogen Sarl Pyrrolobenzodiazepines et conjugues associes
AU2013366490B9 (en) 2012-12-21 2018-02-01 Medimmune Limited Unsymmetrical pyrrolobenzodiazepines-dimers for use in the treatment of proliferative and autoimmune diseases
WO2017185061A1 (fr) 2016-04-21 2017-10-26 Astrocyte Pharmaceuticals, Inc. Composés et procédés pour traiter des états neurologiques et cardiovasculaires
US11839615B2 (en) 2018-02-09 2023-12-12 Astrocyte Pharmaceuticals, Inc. Compounds and methods for treating addiction and related disorders
JP2022502405A (ja) 2018-09-26 2022-01-11 アストロサイト ファーマシューティカルズ， インコーポレイテッド 多形化合物およびその使用
US11813926B2 (en) 2020-08-20 2023-11-14 Denso International America, Inc. Binding agent and olfaction sensor
US11760170B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Olfaction sensor preservation systems and methods
US11881093B2 (en) 2020-08-20 2024-01-23 Denso International America, Inc. Systems and methods for identifying smoking in vehicles
US11636870B2 (en) 2020-08-20 2023-04-25 Denso International America, Inc. Smoking cessation systems and methods
US11760169B2 (en) 2020-08-20 2023-09-19 Denso International America, Inc. Particulate control systems and methods for olfaction sensors
US11828210B2 (en) 2020-08-20 2023-11-28 Denso International America, Inc. Diagnostic systems and methods of vehicles using olfaction
US11932080B2 (en) 2020-08-20 2024-03-19 Denso International America, Inc. Diagnostic and recirculation control systems and methods

Family Cites Families (133)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (fr) 1968-10-17 1970-08-24
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4476301A (en) 1982-04-29 1984-10-09 Centre National De La Recherche Scientifique Oligonucleotides, a process for preparing the same and their application as mediators of the action of interferon
JPS5927900A (ja) 1982-08-09 1984-02-14 Wakunaga Seiyaku Kk 固定化オリゴヌクレオチド
FR2540122B1 (fr) 1983-01-27 1985-11-29 Centre Nat Rech Scient Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application
US4605735A (en) 1983-02-14 1986-08-12 Wakunaga Seiyaku Kabushiki Kaisha Oligonucleotide derivatives
US4948882A (en) 1983-02-22 1990-08-14 Syngene, Inc. Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis
US4824941A (en) 1983-03-10 1989-04-25 Julian Gordon Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems
US4587044A (en) 1983-09-01 1986-05-06 The Johns Hopkins University Linkage of proteins to nucleic acids
US5118800A (en) 1983-12-20 1992-06-02 California Institute Of Technology Oligonucleotides possessing a primary amino group in the terminal nucleotide
US5118802A (en) 1983-12-20 1992-06-02 California Institute Of Technology DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside
US5550111A (en) 1984-07-11 1996-08-27 Temple University-Of The Commonwealth System Of Higher Education Dual action 2',5'-oligoadenylate antiviral derivatives and uses thereof
FR2567892B1 (fr) 1984-07-19 1989-02-17 Centre Nat Rech Scient Nouveaux oligonucleotides, leur procede de preparation et leurs applications comme mediateurs dans le developpement des effets des interferons
US5258506A (en) 1984-10-16 1993-11-02 Chiron Corporation Photolabile reagents for incorporation into oligonucleotide chains
US5430136A (en) 1984-10-16 1995-07-04 Chiron Corporation Oligonucleotides having selectably cleavable and/or abasic sites
US5367066A (en) 1984-10-16 1994-11-22 Chiron Corporation Oligonucleotides with selectably cleavable and/or abasic sites
US4828979A (en) 1984-11-08 1989-05-09 Life Technologies, Inc. Nucleotide analogs for nucleic acid labeling and detection
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
FR2575751B1 (fr) 1985-01-08 1987-04-03 Pasteur Institut Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5405938A (en) 1989-12-20 1995-04-11 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5235033A (en) 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US4762779A (en) 1985-06-13 1988-08-09 Amgen Inc. Compositions and methods for functionalizing nucleic acids
US5317098A (en) 1986-03-17 1994-05-31 Hiroaki Shizuya Non-radioisotope tagging of fragments
JPS638396A (ja) 1986-06-30 1988-01-14 Wakunaga Pharmaceut Co Ltd ポリ標識化オリゴヌクレオチド誘導体
US5264423A (en) 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
ATE113059T1 (de) 1987-06-24 1994-11-15 Florey Howard Inst Nukleosid-derivate.
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US4924624A (en) 1987-10-22 1990-05-15 Temple University-Of The Commonwealth System Of Higher Education 2,',5'-phosphorothioate oligoadenylates and plant antiviral uses thereof
US5188897A (en) 1987-10-22 1993-02-23 Temple University Of The Commonwealth System Of Higher Education Encapsulated 2',5'-phosphorothioate oligoadenylates
US5525465A (en) 1987-10-28 1996-06-11 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates and methods of production and applications of the same
DE3738460A1 (de) 1987-11-12 1989-05-24 Max Planck Gesellschaft Modifizierte oligonukleotide
US5082830A (en) 1988-02-26 1992-01-21 Enzo Biochem, Inc. End labeled nucleotide probe
EP0406309A4 (en) 1988-03-25 1992-08-19 The University Of Virginia Alumni Patents Foundation Oligonucleotide n-alkylphosphoramidates
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US5109124A (en) 1988-06-01 1992-04-28 Biogen, Inc. Nucleic acid probe linked to a label having a terminal cysteine
US5216141A (en) 1988-06-06 1993-06-01 Benner Steven A Oligonucleotide analogs containing sulfur linkages
US5175273A (en) 1988-07-01 1992-12-29 Genentech, Inc. Nucleic acid intercalating agents
US5262536A (en) 1988-09-15 1993-11-16 E. I. Du Pont De Nemours And Company Reagents for the preparation of 5'-tagged oligonucleotides
US5512439A (en) 1988-11-21 1996-04-30 Dynal As Oligonucleotide-linked magnetic particles and uses thereof
US5599923A (en) 1989-03-06 1997-02-04 Board Of Regents, University Of Tx Texaphyrin metal complexes having improved functionalization
US5457183A (en) 1989-03-06 1995-10-10 Board Of Regents, The University Of Texas System Hydroxylated texaphyrins
US5001117A (en) 1989-03-07 1991-03-19 Pharmacaps, Inc. Use of lecithin to restore olfaction and taste
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US4958013A (en) 1989-06-06 1990-09-18 Northwestern University Cholesteryl modified oligonucleotides
US5451463A (en) 1989-08-28 1995-09-19 Clontech Laboratories, Inc. Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides
US5134066A (en) 1989-08-29 1992-07-28 Monsanto Company Improved probes using nucleosides containing 3-dezauracil analogs
US5254469A (en) 1989-09-12 1993-10-19 Eastman Kodak Company Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
US5399676A (en) 1989-10-23 1995-03-21 Gilead Sciences Oligonucleotides with inverted polarity
US5264562A (en) 1989-10-24 1993-11-23 Gilead Sciences, Inc. Oligonucleotide analogs with novel linkages
AU658562B2 (en) 1989-10-24 1995-04-27 Isis Pharmaceuticals, Inc. 2' modified oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
US5292873A (en) 1989-11-29 1994-03-08 The Research Foundation Of State University Of New York Nucleic acids labeled with naphthoquinone probe
US5177198A (en) 1989-11-30 1993-01-05 University Of N.C. At Chapel Hill Process for preparing oligoribonucleoside and oligodeoxyribonucleoside boranophosphates
US5130302A (en) 1989-12-20 1992-07-14 Boron Bilogicals, Inc. Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same
US5486603A (en) 1990-01-08 1996-01-23 Gilead Sciences, Inc. Oligonucleotide having enhanced binding affinity
US5459255A (en) 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US5670633A (en) 1990-01-11 1997-09-23 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides that detect and modulate gene expression
US5587361A (en) 1991-10-15 1996-12-24 Isis Pharmaceuticals, Inc. Oligonucleotides having phosphorothioate linkages of high chiral purity
US5578718A (en) 1990-01-11 1996-11-26 Isis Pharmaceuticals, Inc. Thiol-derivatized nucleosides
US5646265A (en) 1990-01-11 1997-07-08 Isis Pharmceuticals, Inc. Process for the preparation of 2'-O-alkyl purine phosphoramidites
US5681941A (en) 1990-01-11 1997-10-28 Isis Pharmaceuticals, Inc. Substituted purines and oligonucleotide cross-linking
US5214136A (en) 1990-02-20 1993-05-25 Gilead Sciences, Inc. Anthraquinone-derivatives oligonucleotides
AU7579991A (en) 1990-02-20 1991-09-18 Gilead Sciences, Inc. Pseudonucleosides and pseudonucleotides and their polymers
US5321131A (en) 1990-03-08 1994-06-14 Hybridon, Inc. Site-specific functionalization of oligodeoxynucleotides for non-radioactive labelling
US5470967A (en) 1990-04-10 1995-11-28 The Dupont Merck Pharmaceutical Company Oligonucleotide analogs with sulfamate linkages
GB9009980D0 (en) 1990-05-03 1990-06-27 Amersham Int Plc Phosphoramidite derivatives,their preparation and the use thereof in the incorporation of reporter groups on synthetic oligonucleotides
EP0745689A3 (fr) 1990-05-11 1996-12-11 Microprobe Corporation Bâtonnet d'hybridation d'acide nucléique
US5602240A (en) 1990-07-27 1997-02-11 Ciba Geigy Ag. Backbone modified oligonucleotide analogs
US5677437A (en) 1990-07-27 1997-10-14 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5688941A (en) 1990-07-27 1997-11-18 Isis Pharmaceuticals, Inc. Methods of making conjugated 4' desmethyl nucleoside analog compounds
US5541307A (en) 1990-07-27 1996-07-30 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs and solid phase synthesis thereof
US5218105A (en) 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5608046A (en) 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5618704A (en) 1990-07-27 1997-04-08 Isis Pharmacueticals, Inc. Backbone-modified oligonucleotide analogs and preparation thereof through radical coupling
BR9106702A (pt) 1990-07-27 1993-06-08 Isis Pharmaceuticals Inc Analogo de oligonucleotideos e processos para modular a producao de uma proteina por um organismo e para tratar um organismo
US5610289A (en) 1990-07-27 1997-03-11 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogues
US5138045A (en) 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5489677A (en) 1990-07-27 1996-02-06 Isis Pharmaceuticals, Inc. Oligonucleoside linkages containing adjacent oxygen and nitrogen atoms
US5623070A (en) 1990-07-27 1997-04-22 Isis Pharmaceuticals, Inc. Heteroatomic oligonucleoside linkages
US5245022A (en) 1990-08-03 1993-09-14 Sterling Drug, Inc. Exonuclease resistant terminally substituted oligonucleotides
CA2088673A1 (fr) 1990-08-03 1992-02-04 Alexander L. Weis Composes et methodes pour l'inhibition de l'expression genique
US5177196A (en) 1990-08-16 1993-01-05 Microprobe Corporation Oligo (α-arabinofuranosyl nucleotides) and α-arabinofuranosyl precursors thereof
US5512667A (en) 1990-08-28 1996-04-30 Reed; Michael W. Trifunctional intermediates for preparing 3'-tailed oligonucleotides
US5214134A (en) 1990-09-12 1993-05-25 Sterling Winthrop Inc. Process of linking nucleosides with a siloxane bridge
US5561225A (en) 1990-09-19 1996-10-01 Southern Research Institute Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
EP0549686A4 (en) 1990-09-20 1995-01-18 Gilead Sciences Inc Modified internucleoside linkages
US5432272A (en) 1990-10-09 1995-07-11 Benner; Steven A. Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases
CA2095212A1 (fr) 1990-11-08 1992-05-09 Sudhir Agrawal Incorporation de multiples groupes de ligands sur des oligonucleotides synthetiques
US5714331A (en) 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US5719262A (en) 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US5539082A (en) 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
US5371241A (en) 1991-07-19 1994-12-06 Pharmacia P-L Biochemicals Inc. Fluorescein labelled phosphoramidites
US5571799A (en) 1991-08-12 1996-11-05 Basco, Ltd. (2'-5') oligoadenylate analogues useful as inhibitors of host-v5.-graft response
EP0538194B1 (fr) 1991-10-17 1997-06-04 Novartis AG Nucléosides et oligonucléosides bicycliques, leur procédé de préparation et leurs intermédiaires
US5594121A (en) 1991-11-07 1997-01-14 Gilead Sciences, Inc. Enhanced triple-helix and double-helix formation with oligomers containing modified purines
US5484908A (en) 1991-11-26 1996-01-16 Gilead Sciences, Inc. Oligonucleotides containing 5-propynyl pyrimidines
US5359044A (en) 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
US5595726A (en) 1992-01-21 1997-01-21 Pharmacyclics, Inc. Chromophore probe for detection of nucleic acid
US5565552A (en) 1992-01-21 1996-10-15 Pharmacyclics, Inc. Method of expanded porphyrin-oligonucleotide conjugate synthesis
FR2687679B1 (fr) 1992-02-05 1994-10-28 Centre Nat Rech Scient Oligothionucleotides.
US5633360A (en) 1992-04-14 1997-05-27 Gilead Sciences, Inc. Oligonucleotide analogs capable of passive cell membrane permeation
US5434257A (en) 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
EP0577558A2 (fr) 1992-07-01 1994-01-05 Ciba-Geigy Ag Nucléosides carbocycliques contenant des noyaux bicycliques, oligonucléotides en dérivant, procédé pour leur préparation, leur application et des intermédiaires
US5272250A (en) 1992-07-10 1993-12-21 Spielvogel Bernard F Boronated phosphoramidate compounds
US5574142A (en) 1992-12-15 1996-11-12 Microprobe Corporation Peptide linkers for improved oligonucleotide delivery
US5476925A (en) 1993-02-01 1995-12-19 Northwestern University Oligodeoxyribonucleotides including 3'-aminonucleoside-phosphoramidate linkages and terminal 3'-amino groups
GB9304618D0 (en) 1993-03-06 1993-04-21 Ciba Geigy Ag Chemical compounds
DK0691968T3 (da) 1993-03-30 1998-02-23 Sanofi Sa Acykliske nukleosid-analoge og oligonukleotidsekvenser indeholdende disse
JPH08508491A (ja) 1993-03-31 1996-09-10 スターリング ウインスロップ インコーポレイティド ホスホジエステル結合をアミド結合に置き換えたオリゴヌクレオチド
DE4311944A1 (de) 1993-04-10 1994-10-13 Degussa Umhüllte Natriumpercarbonatpartikel, Verfahren zu deren Herstellung und sie enthaltende Wasch-, Reinigungs- und Bleichmittelzusammensetzungen
US5502177A (en) 1993-09-17 1996-03-26 Gilead Sciences, Inc. Pyrimidine derivatives for labeled binding partners
US5457187A (en) 1993-12-08 1995-10-10 Board Of Regents University Of Nebraska Oligonucleotides containing 5-fluorouracil
US5446137B1 (en) 1993-12-09 1998-10-06 Behringwerke Ag Oligonucleotides containing 4'-substituted nucleotides
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5596091A (en) 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
US5627053A (en) 1994-03-29 1997-05-06 Ribozyme Pharmaceuticals, Inc. 2'deoxy-2'-alkylnucleotide containing nucleic acid
US5625050A (en) 1994-03-31 1997-04-29 Amgen Inc. Modified oligonucleotides and intermediates useful in nucleic acid therapeutics
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US5597696A (en) 1994-07-18 1997-01-28 Becton Dickinson And Company Covalent cyanine dye oligonucleotide conjugates
US5597909A (en) 1994-08-25 1997-01-28 Chiron Corporation Polynucleotide reagents containing modified deoxyribose moieties, and associated methods of synthesis and use
US5580731A (en) 1994-08-25 1996-12-03 Chiron Corporation N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith
US6063596A (en) * 1997-12-11 2000-05-16 Incyte Pharmaceuticals, Inc. G-protein coupled receptors associated with immune response
US20010025099A1 (en) * 1998-02-20 2001-09-27 Nabil Elshourbagy G protein-coupled receptor polypeptides and polyncleotides
US6150409A (en) 1998-10-23 2000-11-21 Monell Chemical Senses Center Adjuvants and methods for raising intracellular calcium ion concentration
EP1624753B1 (fr) 2002-11-21 2012-01-25 The University of Utah Research Foundation Modulation purinergique d'odeur

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"Remington: The Science and Practice of Pharmacy", 1995, MACK PUBLISHING COMPANY
BIOCHEM. PHARMACOL, vol. 42, 1991, pages 2062 - 2065
CANCER RESEARCH, vol. 49, 1989, pages 6214 - 6220
CARR, W. E. ET AL., ENVIRON. HEALTH PERSPECT., vol. 71, 1987, pages 31 - 46
IMMUNOLOG. REVIEWS, vol. 129, 1992, pages 57 - 80
LITZINGER, HUANG, BIOCHIMICA ET BIOPHYSICA ACTA, vol. 1104, 1992, pages 179 - 187
NEEDLEMAN, WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443
PEARSON, LIPMAN, PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 2444
SMITH, WATERMAN, ADV. APPL. MATH., vol. 2, 1981, pages 482
WOLFF, J. A. ET AL., SCIENCE, vol. 247, 1990, pages 1465 - 1468
WOLFF, J. A., NATURE, vol. 352, 1991, pages 815 - 818

Cited By (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344860B2 (en) 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
EP3858387A1 (fr) 2003-11-06 2021-08-04 Seagen Inc. Composés de monométhylvaline capables de conjugaison aux ligands
EP3434275A1 (fr) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Méthode de dépistage de cellules cancéreuses basé sur l'utilisation de conjugués d'auristatin avec anticorps
EP2486933A1 (fr) 2003-11-06 2012-08-15 Seattle Genetics, Inc. Composés de monométhylvaline conjugués avec des anticorps
EP2489364A1 (fr) 2003-11-06 2012-08-22 Seattle Genetics, Inc. Composés de monométhylvaline conjuguös avec des anticorps
EP2260858A2 (fr) 2003-11-06 2010-12-15 Seattle Genetics, Inc. Composés de monométhylvaline capable de conjugaison aux lignads.
EP2478912A1 (fr) 2003-11-06 2012-07-25 Seattle Genetics, Inc. Conjugués d'auristatin avec des anticorps dirigés contre le HER2 ou le CD22 et leur usage thérapeutique
EP3120861A1 (fr) 2003-11-06 2017-01-25 Seattle Genetics, Inc. Composés intermédiaires pour la préparation de conjugués d'auristatin avec des éléments de liaison
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
WO2005100990A2 (fr) * 2004-04-13 2005-10-27 Bayer Healthcare Ag Methodes diagnostiques et therapeutiques pour des maladies associees au purinocepteur 2 de type y (p2y2)
WO2005100990A3 (fr) * 2004-04-13 2006-03-02 Bayer Healthcare Ag Methodes diagnostiques et therapeutiques pour des maladies associees au purinocepteur 2 de type y (p2y2)
EP2286844A2 (fr) 2004-06-01 2011-02-23 Genentech, Inc. Conjugués anticorps-médicament et procédés
EP3088004A1 (fr) 2004-09-23 2016-11-02 Genentech, Inc. Anticorps et conjugués modifiés au niveau des cystéines
WO2006052007A1 (fr) * 2004-11-11 2006-05-18 Takeda Pharmaceutical Company Limited Agent de régulation de glycémie
GB2446735A (en) * 2005-10-07 2008-08-20 Imp College Innovations Ltd Modulators of the purinergic signalling pathway for treating sodium homeostatis hypertension and aldosteronism
WO2007042776A1 (fr) * 2005-10-07 2007-04-19 Imperial College Innovations Limited Modulateurs de la voie de signalisation purinergique pour traiter l'homeostasie du sodium, l'hypertension et l'hyperaldosteronisme
WO2011000054A1 (fr) 2009-07-03 2011-01-06 Avipep Pty Ltd Immunoconjugués et leurs procédés de production
WO2011031870A1 (fr) 2009-09-09 2011-03-17 Centrose, Llc Conjugués médicamenteux ciblés à visée extracellulaire
WO2011056983A1 (fr) 2009-11-05 2011-05-12 Genentech, Inc. Conjugués d'anticorps modifiés par cystéine, radiomarqués par le zirconium
WO2011075786A1 (fr) 2009-12-23 2011-06-30 Avipep Pty Ltd Immuno-conjugués et leurs méthodes de production
WO2011130598A1 (fr) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazépines et conjugués de celles-ci
WO2011156328A1 (fr) 2010-06-08 2011-12-15 Genentech, Inc. Anticorps et conjugués modifiés par la cystéine
WO2012074757A1 (fr) 2010-11-17 2012-06-07 Genentech, Inc. Conjugués d'anticorps alaninyl-maytansinol
WO2012142662A1 (fr) 2011-04-21 2012-10-26 Garvan Institute Of Medical Research Molécules à domaine variable modifié et procédés de préparation et d'utilisation de celles-ci
EP3103810A2 (fr) 2011-04-21 2016-12-14 Garvan Institute of Medical Research Molécules à domaine variable modifié et procédés de préparation et d'utilisation de celles-ci
WO2012155019A1 (fr) 2011-05-12 2012-11-15 Genentech, Inc. Procédé lc-ms/ms de surveillance de réactions multiples pour détecter des anticorps thérapeutiques dans des échantillons animaux à l'aide de peptides de signature d'infrastructure
US11135303B2 (en) 2011-10-14 2021-10-05 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
US10780181B2 (en) 2012-10-12 2020-09-22 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10695433B2 (en) 2012-10-12 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10799596B2 (en) 2012-10-12 2020-10-13 Adc Therapeutics S.A. Pyrrolobenzodiazepine-antibody conjugates
US9919056B2 (en) 2012-10-12 2018-03-20 Adc Therapeutics S.A. Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
US10751346B2 (en) 2012-10-12 2020-08-25 Medimmune Limited Pyrrolobenzodiazepine—anti-PSMA antibody conjugates
US10736903B2 (en) 2012-10-12 2020-08-11 Medimmune Limited Pyrrolobenzodiazepine-anti-PSMA antibody conjugates
WO2014057074A1 (fr) 2012-10-12 2014-04-17 Spirogen Sàrl Pyrrolobenzodiazépines et leurs conjugués
EP2839860A1 (fr) 2012-10-12 2015-02-25 Spirogen Sàrl Pyrrolobenzodiazépines et ses conjugués
US11779650B2 (en) 2012-10-12 2023-10-10 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10722594B2 (en) 2012-10-12 2020-07-28 Adc Therapeutics S.A. Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
US9931415B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10646584B2 (en) 2012-10-12 2020-05-12 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US11690918B2 (en) 2012-10-12 2023-07-04 Medimmune Limited Pyrrolobenzodiazepine-anti-CD22 antibody conjugates
US11701430B2 (en) 2012-10-12 2023-07-18 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10335497B2 (en) 2012-10-12 2019-07-02 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US11771775B2 (en) 2012-10-12 2023-10-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9889207B2 (en) 2012-10-12 2018-02-13 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
US10994023B2 (en) 2012-10-12 2021-05-04 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2014159981A2 (fr) 2013-03-13 2014-10-02 Spirogen Sarl Pyrrolobenzodiazépines et leurs conjugués
WO2014140862A2 (fr) 2013-03-13 2014-09-18 Spirogen Sarl Pyrrolobenzodiazépines et leurs conjugués
WO2014140174A1 (fr) 2013-03-13 2014-09-18 Spirogen Sàrl Pyrrolobenzodiazépines et leurs conjugués
WO2015023355A1 (fr) 2013-08-12 2015-02-19 Genentech, Inc. Conjugués anticorps-médicament dimérique 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
US9950078B2 (en) 2013-10-11 2018-04-24 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US9956299B2 (en) 2013-10-11 2018-05-01 Medimmune Limited Pyrrolobenzodiazepine—antibody conjugates
US10010624B2 (en) 2013-10-11 2018-07-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US10029018B2 (en) 2013-10-11 2018-07-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2015095212A1 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés conjugués anticorps-médicament dimérique à base de 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
WO2015095227A2 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
WO2015095223A2 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composés peptidomimétiques et conjugués anticorps-médicament de ceux-ci
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2016037644A1 (fr) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazépines et leurs conjugués
WO2016040825A1 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Intermédiaires disulfure d'anthracycline, conjugué anticorps-médicaments et procédés
WO2016040856A2 (fr) 2014-09-12 2016-03-17 Genentech, Inc. Anticorps et conjugués modifiés génétiquement avec de la cystéine
US10420777B2 (en) 2014-09-12 2019-09-24 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3235820A1 (fr) 2014-09-17 2017-10-25 Genentech, Inc. Pyrrolobenzodiazépines et conjugués à base de disulfure d'anticorps associés
US10780096B2 (en) 2014-11-25 2020-09-22 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
WO2016090050A1 (fr) 2014-12-03 2016-06-09 Genentech, Inc. Composés d'amine quaternaire et conjugués anticorps-médicament de ceux-ci
US11702473B2 (en) 2015-04-15 2023-07-18 Medimmune Limited Site-specific antibody-drug conjugates
US11059893B2 (en) 2015-04-15 2021-07-13 Bergenbio Asa Humanized anti-AXL antibodies
WO2017059289A1 (fr) 2015-10-02 2017-04-06 Genentech, Inc. Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
WO2017064675A1 (fr) 2015-10-16 2017-04-20 Genentech, Inc. Conjugués médicamenteux à pont disulfure encombré
WO2017068511A1 (fr) 2015-10-20 2017-04-27 Genentech, Inc. Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
WO2017123633A1 (fr) * 2016-01-11 2017-07-20 Dignity Health Modulateurs des canaux cationiques activés par le zinc
US10392393B2 (en) 2016-01-26 2019-08-27 Medimmune Limited Pyrrolobenzodiazepines
US10695439B2 (en) 2016-02-10 2020-06-30 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11517626B2 (en) 2016-02-10 2022-12-06 Medimmune Limited Pyrrolobenzodiazepine antibody conjugates
EP4273551A2 (fr) 2016-03-25 2023-11-08 F. Hoffmann-La Roche AG Dosage multiplexé pour la quantification d'anticorps totaux et de médicaments conjugués à des anticorps
WO2017165734A1 (fr) 2016-03-25 2017-09-28 Genentech, Inc. Dosage multiplexé pour la quantification d'anticorps totaux et de médicaments conjugués à des anticorps
US10543279B2 (en) 2016-04-29 2020-01-28 Medimmune Limited Pyrrolobenzodiazepine conjugates and their use for the treatment of cancer
WO2017201449A1 (fr) 2016-05-20 2017-11-23 Genentech, Inc. Conjugués anticorps-protac et procédés d'utilisation
WO2017205741A1 (fr) 2016-05-27 2017-11-30 Genentech, Inc. Procédé bioanalytique pour la caractérisation de conjugués anticorps-médicament spécifiques d'un site
WO2017214024A1 (fr) 2016-06-06 2017-12-14 Genentech, Inc. Médicaments conjugués d'anticorps silvestrol et procédés d'utilisation
WO2018031662A1 (fr) 2016-08-11 2018-02-15 Genentech, Inc. Promédicaments de pyrrolobenzodiazépine et conjugués d'anticorps de ceux-ci
WO2018065501A1 (fr) 2016-10-05 2018-04-12 F. Hoffmann-La Roche Ag Procédés de préparation de conjugués anticorps-médicament
US10799595B2 (en) 2016-10-14 2020-10-13 Medimmune Limited Pyrrolobenzodiazepine conjugates
US11612665B2 (en) 2017-02-08 2023-03-28 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US11813335B2 (en) 2017-02-08 2023-11-14 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
US11370801B2 (en) 2017-04-18 2022-06-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
US10544223B2 (en) 2017-04-20 2020-01-28 Adc Therapeutics Sa Combination therapy with an anti-axl antibody-drug conjugate
US11318211B2 (en) 2017-06-14 2022-05-03 Adc Therapeutics Sa Dosage regimes for the administration of an anti-CD19 ADC
US11938192B2 (en) 2017-06-14 2024-03-26 Medimmune Limited Dosage regimes for the administration of an anti-CD19 ADC
US11649250B2 (en) 2017-08-18 2023-05-16 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2019060398A1 (fr) 2017-09-20 2019-03-28 Ph Pharma Co., Ltd. Analogues de thailanstatine
US11352324B2 (en) 2018-03-01 2022-06-07 Medimmune Limited Methods
US11524969B2 (en) 2018-04-12 2022-12-13 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof as antitumour agents
WO2020049286A1 (fr) 2018-09-03 2020-03-12 Femtogenix Limited Amides polycycliques servant d'agents cytotoxiques
WO2020086858A1 (fr) 2018-10-24 2020-04-30 Genentech, Inc. Inducteurs chimiques conjugués de dégradation et méthodes d'utilisation
WO2020123275A1 (fr) 2018-12-10 2020-06-18 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
WO2020157491A1 (fr) 2019-01-29 2020-08-06 Femtogenix Limited Agents cytotoxiques de réticulation g-a
WO2020227159A2 (fr) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Métodes de modulation de l'activité immunitaire
WO2022023735A1 (fr) 2020-07-28 2022-02-03 Femtogenix Limited Agents cytotoxiques

Also Published As

Publication number Publication date
AU2003294462A1 (en) 2004-06-18
US20060264398A1 (en) 2006-11-23
WO2004047749A3 (fr) 2004-10-21
EP1624753A4 (fr) 2007-11-07
US7557092B2 (en) 2009-07-07
AU2003294462B2 (en) 2010-10-28
ATE542423T1 (de) 2012-02-15
EP1624753A2 (fr) 2006-02-15
AU2003294462C1 (en) 2011-06-30
EP1624753B1 (fr) 2012-01-25
CA2507044A1 (fr) 2004-06-10
EP2410332A1 (fr) 2012-01-25

Similar Documents

Publication Publication Date Title
AU2003294462B2 (en) Purinergic modulation of smell
Kwak et al. Astrocytes control sensory acuity via tonic inhibition in the thalamus
Hegg et al. Activation of purinergic receptor subtypes modulates odor sensitivity
Shibuya et al. Evidence that multiple P2X purinoceptors are functionally expressed in rat supraoptic neurones
Weick et al. P2 receptors in satellite glial cells in trigeminal ganglia of mice
North et al. Pharmacology of cloned P2X receptors
Saul et al. Heteromeric assembly of P2X subunits
Schwiebert et al. Extracellular ATP as a signaling molecule for epithelial cells
Molliver et al. ATP and UTP excite sensory neurons and induce CREB phosphorylation through the metabotropic receptor, P2Y2
Emmett et al. Characterization of ionotrophic purinergic receptors in hepatocytes
Lewis et al. Lack of run‐down of smooth muscle P2X receptor currents recorded with the amphotericin permeabilized patch technique, physiological and pharmacological characterization of the properties of mesenteric artery P2X receptor ion channels
Turner et al. The P2 nucleotide receptors
Papp et al. P2X receptor activation elicits transporter-mediated noradrenaline release from rat hippocampal slices
Heinrich et al. Modulation of neurotransmitter release by P2X and P2Y receptors in the rat spinal cord
Unterberger et al. Inhibition of adenylyl cyclase by neuronal P2Y receptors
Huang et al. ATP augments peptide release from rat sensory neurons in culture through activation of P2Y receptors
López-Castejón et al. Characterization of ATP-gated P2X7 receptors in fish provides new insights into the mechanism of release of the leaderless cytokine interleukin-1β
Palmer et al. Stable knockdown of CFTR establishes a role for the channel in P2Y receptor‐stimulated anion secretion
Moskvina et al. Activity-dependent autocrine-paracrine activation of neuronal P2Y receptors
Poulopoulou et al. Extracellular 3′, 5′ cyclic guanosine monophosphate inhibits kainate-activated responses in cultured mouse cerebellar neurons
Garcia‐Marcos et al. Membrane compartments and purinergic signalling: the role of plasma membrane microdomains in the modulation of P2XR‐mediated signalling
Lee et al. ATP stimulates Na+-glucose cotransporter activity via cAMP and p38 MAPK in renal proximal tubule cells
Brosenitsch et al. Developmental downregulation of P2X3 receptors in motoneurons of the compact formation of the nucleus ambiguus
Netzeband et al. Chronic ethanol treatment alters AMPA-induced calcium signals in developing Purkinje neurons
Stephenson Excitation of skinned muscle fibers by imposed ion gradients. II. Influence of quercetin and ATP removal on the Ca2+-insensitive component of stimulated 45Ca efflux.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2507044

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003294462

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003789946

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003789946

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006264398

Country of ref document: US

Ref document number: 10535774

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP

WWP Wipo information: published in national office

Ref document number: 10535774

Country of ref document: US